Remedies for pain have progressed beyond the one recommended in Shakespeare’s Romeo and Juliet, where the renowned playwright wrote, “One pain is lessened by another; catch some new infection… and the poison of the old one will die.” Today, a variety of treatment options are available to the sufferer. Alas, many of these come bundled with pernicious side effects and the risk of addiction, making the remedy, in the long term, worse than the ailment. With NeuroRelease™, Cambridge, Massachusetts-based PixarBio Corporation (OTCQX: PXRB) is offering the possibility of release not only from pain but also from dependence on painkillers.
Pain is a ubiquitous phenomenon that pervades our lives from cradle to grave. We bear its lesser manifestations with a grimace or a smile, but, in many instances, analgesics are needed to free us from the greatest torments. For centuries, extracts from opium, derived from the poppy plant, have served that purpose. Perhaps, the most significant of these extracts or alkoloids is morphine, named after Morpheus, the Greek god of dreams.
Morphine, in one form or another, has been used to ease pain since it was isolated from raw opium in 1805. Before that time, a number of preparations, such as laudanum, a solution of opium in alcohol, were employed as painkillers. Morphine is, however, treacherously addictive. Its use during the American Civil War turned large numbers of wounded veterans into addicts. This spurred the search for less addictive analgesics and the employment of weaker opiates such as codeine, which was widely used, at one time, in cough medications.
The quest for less addictive opiates, ironically, led to the discovery of more addictive ones. The German chemist, Felix Hoffman, developed heroin while working in the pharmaceutical research department of what is now Bayer AG. Bayer actually manufactured and sold bottles of heroin medicine in the first decade of the twentieth century (http://dtn.fm/Fw8dD).
In 1909, the U.S. Congress passed the Smoking Opium Exclusion Act, which banned the importation, possession and use of ‘smoking opium’. The statute still allowed for the use of opium-based ‘medications’, however. It was actually the first federal law banning the non-medical use of a substance.
Since that time, a number of FDA-approved drugs have made their appearance, including Vicodin in 1984, OxyContin in 1995 and Percocet in 1999. These are, essentially, all synthetic opiates and, like their natural cousins, are just as addictive. As a result, opioid addiction has mushroomed into a national crisis. The U.S. Department of Health and Human Services (HHS) (http://dtn.fm/2qeUg) has stated that “more people died from drug overdoses in 2014 than in any year on record, and the majority of drug overdose deaths (more than six out of ten) involved an opioid.”
This frightening scenario makes PixarBio’s NeuroRelease™ a welcome addition to the analgesic arsenal. NeuroRelease™ is a morphine replacement, non-addictive pain platform for the surgical and hospital setting, for the battlefield, and for the alleviation of acute and chronic pain in general. The first product FDA approval for the platform is expected to be a 14-day post-surgical pain treatment, and the company anticipates commercial approval for this indication in late 2018.
PixarBio is a specialty pharmaceutical and biotech company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. The company researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Its lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models.
For more information, visit www.PixarBio.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, December 27, 2016
Friday, December 23, 2016
FTE Networks, Inc. (FTNW) is Enabling the Connection
In less than a decade, we’ve seen multiple networks spring up that are now connecting hundreds of millions of people. The largest one, Facebook, surpassed an astounding one billion users earlier this year as it advanced on its mission to “connect the world”. Facebook, as well as other networks sharing the same goal, is achieving great success by connecting more and more people every day. However, they can’t do that alone.
FTE Networks (OTCQX: FTNW) lives by the mission of “enabling the connection” that is allowing so many businesses to thrive in today’s globally connected environment. The company provides end-to-end network infrastructure solutions and focuses primarily on the burgeoning technology & communications networks industries. Current customers and target markets include tier 1 & 2 carriers, network infrastructure providers, OEMs, major ISPs and government.
When you consider just a few of the latest statistics, it becomes clear how much this company’s services are needed. Today, there are approximately 7.3 billion people, 3.4 billion internet users, and 2.3 billion active social media users. And all those numbers are growing. Networks will soon need to have the capacity to connect hundreds of millions of new people, and significant constraints or delays won’t be acceptable.
FTE Networks’ strategy includes optimizing its customer base through strategic partnerships, expanding recurring revenue with high margins, pursuing continuous improvement, leveraging innovative technology and expertise, deploying a world-class managed network services platform and capturing new growth opportunities on an ongoing basis. The strategy is clearly working well, with 19 locations across the country, favorable growth characteristics, and continued momentum heading into 2017.
Looking back over 2016, revenue increased significantly, and the final total is expected to be 50% greater than what was generated in 2015. There have also been tremendous gains in gross profits, with the third quarter bringing in $1.4 million, which is a 159% increase from the same period last year. Additionally, gross margins were improved from 14% to 37% year-over-year, and the company achieved positive income from operations.
In a recent news release, Chairman and SEO Michael Palleschi stated that not only will the company finish strong this year, but it is anticipated that the company will continue to drive incremental growth quarter-over-quarter throughout 2017 and beyond. As we enter 2017, FTE Networks will focus on pursuing accretive growth opportunities through mergers and acquisitions that are expected to solidify its position as a leader in the infrastructure solutions business segments, while also accelerating the launch of its exciting Managed Services platform.
With a track record of success already established, this is a company you will want to keep on your radar screen.
For more information, visit www.FTENet.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
FTE Networks (OTCQX: FTNW) lives by the mission of “enabling the connection” that is allowing so many businesses to thrive in today’s globally connected environment. The company provides end-to-end network infrastructure solutions and focuses primarily on the burgeoning technology & communications networks industries. Current customers and target markets include tier 1 & 2 carriers, network infrastructure providers, OEMs, major ISPs and government.
When you consider just a few of the latest statistics, it becomes clear how much this company’s services are needed. Today, there are approximately 7.3 billion people, 3.4 billion internet users, and 2.3 billion active social media users. And all those numbers are growing. Networks will soon need to have the capacity to connect hundreds of millions of new people, and significant constraints or delays won’t be acceptable.
FTE Networks’ strategy includes optimizing its customer base through strategic partnerships, expanding recurring revenue with high margins, pursuing continuous improvement, leveraging innovative technology and expertise, deploying a world-class managed network services platform and capturing new growth opportunities on an ongoing basis. The strategy is clearly working well, with 19 locations across the country, favorable growth characteristics, and continued momentum heading into 2017.
Looking back over 2016, revenue increased significantly, and the final total is expected to be 50% greater than what was generated in 2015. There have also been tremendous gains in gross profits, with the third quarter bringing in $1.4 million, which is a 159% increase from the same period last year. Additionally, gross margins were improved from 14% to 37% year-over-year, and the company achieved positive income from operations.
In a recent news release, Chairman and SEO Michael Palleschi stated that not only will the company finish strong this year, but it is anticipated that the company will continue to drive incremental growth quarter-over-quarter throughout 2017 and beyond. As we enter 2017, FTE Networks will focus on pursuing accretive growth opportunities through mergers and acquisitions that are expected to solidify its position as a leader in the infrastructure solutions business segments, while also accelerating the launch of its exciting Managed Services platform.
With a track record of success already established, this is a company you will want to keep on your radar screen.
For more information, visit www.FTENet.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
At National Waste Management Holdings, Inc. (NWMH), Diverse Revenue Streams lead to Healthy Cash Flow
With close to half a million sitting in the bank and in short-term securities at the end of the third quarter (September 30, 2016), National Waste Management Holdings, Inc. (OTC: NWMH) is flush with cash. This is no happenstance or accident. The company plans to become a vertically integrated behemoth with the long-term goal of servicing the entire East Coast from Florida to New York.
National Waste plans to achieve that vertical integration mainly through acquisitions, a strategy that is already proving to be a huge success. Its revenues for the nine-month period ended September 2016 were $4.9 million, rising by 262 percent over 2015 same period revenues of $1.3 million. Management at National Waste may be forgiven for laughing all the way to the bank. Cash and cash equivalents increased by 31 percent. This is one waste management company that’s wasting no time as it vigorously pursues its objective of becoming a major player in the industry.
A vertically integrated company is one that owns or controls successive stages in the supply chain. Since the end product of one stage would normally be the input to another stage, a vertical integration approach has the potential of streamlining processes and reducing costs. The major oil companies have employed such a strategy with telling effect, with interests in the supply chain from exploration to gas stations.
The waste management business has a similar heterogeneous value chain, composed of landfills, transfer stations, residential dumpster service, commercial dumpster service and residential garbage collection. National Waste, with the complementary strategies of acquisition and vertical integration, has been adding services as quickly as it has been extending its geographic reach.
Two of the driving forces behind National Waste’s winning strategy were interviewed by NetworkNewsWire (NNW), the multifaceted financial news and publishing company. CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor sat down with Stuart Smith to discuss the company’s past milestones and its future goals.
With some 25 years of experience in the solid waste industry under his belt, CEO Louis “Tiny” Paveglio is a bright star in the National Waste firmament. He started as Vice President of Waste Recovery, a position from which he managed day-to-day operations and focused on revenue generation and gross margin profitability.
Under his leadership, Waste Recovery has expanded its roll-offs, built a solid waste transfer station and expanded residential garbage routes. In 2002, Paveglio was made CEO of Sandland, another Teelon company. As CEO, Paveglio made many significant changes to increase productivity and efficiencies.
After some restructuring, he increased profits while the downturn in new construction was hitting the C&D industry. He diversified to keep increasing revenue by trucking recycled materials to other various facilities, saving airspace at the landfill while fulfilling the need for recycled materials. When Sandland was acquired by National Waste, Paveglio assumed the position of CEO.
Dali Kranzthor is CFO of National Waste. As a certified valuation analyst, he is proficient in valuing companies and has assisted clients in this capacity with mergers and acquisitions and tax compliance. Before joining National Waste, he worked for many years at a full service CPA firm as director of audit and assurance and valuation.
For more information, visit the company’s website at www.nationalwastemgmt.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
National Waste plans to achieve that vertical integration mainly through acquisitions, a strategy that is already proving to be a huge success. Its revenues for the nine-month period ended September 2016 were $4.9 million, rising by 262 percent over 2015 same period revenues of $1.3 million. Management at National Waste may be forgiven for laughing all the way to the bank. Cash and cash equivalents increased by 31 percent. This is one waste management company that’s wasting no time as it vigorously pursues its objective of becoming a major player in the industry.
A vertically integrated company is one that owns or controls successive stages in the supply chain. Since the end product of one stage would normally be the input to another stage, a vertical integration approach has the potential of streamlining processes and reducing costs. The major oil companies have employed such a strategy with telling effect, with interests in the supply chain from exploration to gas stations.
The waste management business has a similar heterogeneous value chain, composed of landfills, transfer stations, residential dumpster service, commercial dumpster service and residential garbage collection. National Waste, with the complementary strategies of acquisition and vertical integration, has been adding services as quickly as it has been extending its geographic reach.
Two of the driving forces behind National Waste’s winning strategy were interviewed by NetworkNewsWire (NNW), the multifaceted financial news and publishing company. CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor sat down with Stuart Smith to discuss the company’s past milestones and its future goals.
With some 25 years of experience in the solid waste industry under his belt, CEO Louis “Tiny” Paveglio is a bright star in the National Waste firmament. He started as Vice President of Waste Recovery, a position from which he managed day-to-day operations and focused on revenue generation and gross margin profitability.
Under his leadership, Waste Recovery has expanded its roll-offs, built a solid waste transfer station and expanded residential garbage routes. In 2002, Paveglio was made CEO of Sandland, another Teelon company. As CEO, Paveglio made many significant changes to increase productivity and efficiencies.
After some restructuring, he increased profits while the downturn in new construction was hitting the C&D industry. He diversified to keep increasing revenue by trucking recycled materials to other various facilities, saving airspace at the landfill while fulfilling the need for recycled materials. When Sandland was acquired by National Waste, Paveglio assumed the position of CEO.
Dali Kranzthor is CFO of National Waste. As a certified valuation analyst, he is proficient in valuing companies and has assisted clients in this capacity with mergers and acquisitions and tax compliance. Before joining National Waste, he worked for many years at a full service CPA firm as director of audit and assurance and valuation.
For more information, visit the company’s website at www.nationalwastemgmt.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Biotricity, Inc. (BTCY) – A Modern Technology Company for Medical and Consumer Markets
Modern technological advancements are permeating all facets of society and industry and encouraging remote interactions from anywhere and at anytime. In the realm of education, we have seen a rise in the offering of massive open online courses (MOOCs) aimed at unlimited student participation and open access via the web. In the financial services arena, we have seen the rapid growth of technology-driven companies enabling mobile payments and value-added transactional services via e-commerce sites and point-of-sale solutions. It was only a matter of time before we began looking more closely at how the latest developments in technology are influencing the medical field and the way doctors care for patients.
On December 20, 2017, only days before the dawn of the coming new year, SeeThruEquity – an independent equity research firm focused on small cap and micro cap public companies – brought this medical consideration to the general public when it issued a press release (http://dtn.fm/ky37V) highlighting its initiation of coverage on Biotricity, Inc. (OTCQB: BTCY). SeeThruEquity estimated a 12-month price target of $4.20 for the company.
Biotricity is an emerging medical technology company that is focused on preventative health solutions. The company concentrates on developing and delivering remote patient monitoring and connected health solutions for disease management and lifestyle improvement in both diagnostic and post-diagnostic settings. With an eye toward putting health management into the hands of the patient, the company uses proprietary technology to develop cutting-edge solutions that empower the self-management of critical and chronic conditions and ease the rising burden on the health care system.
At present, Biotricity is directing its lead product, Bioflux, toward the monitoring of cardiovascular disease (CVD). With Bioflux, the company has designed a wearable mobile device and echocardiogram (ECG) system that boosts a doctor’s ability to monitor and diagnose CVD. Bioflux allows doctors to detect CVD or coronary heart diseases while also serving as an ambulatory monitor capable of identifying arrhythmias; acting as a remote mobile cardiac telemetry diagnostic monitor; and communicating ECG data via a built-in cellular radio in real-time. As a result, Biotricity’s management team is pursuing a 510(k) regulatory pathway for Bioflux and expecting to receive clearance to market the device in the first quarter of 2017.
In the future, the company intends to look beyond Bioflux at other sectors that present opportunities for long-term growth. For example, Biotricity intends to launch its Biolife health and lifestyle solution for the chronic illness side of the consumer market in 2017, aiming it at those individuals with high risks of CVD or who are already diagnosed with it. The Biolife solution consists of a clinical-grade heart monitor that reads ECG data or heart rhythms, as well as respiration, calories, temperature, physical activity and more. Additionally, the company plans to introduce products that target sleep apnea, fetal ECG monitoring, and diabetes monitoring to the wider healthcare market, as these three medical areas represent multi-billion dollar opportunities, if the company successfully executes its plan.
For more information, visit www.Biotricity.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
On December 20, 2017, only days before the dawn of the coming new year, SeeThruEquity – an independent equity research firm focused on small cap and micro cap public companies – brought this medical consideration to the general public when it issued a press release (http://dtn.fm/ky37V) highlighting its initiation of coverage on Biotricity, Inc. (OTCQB: BTCY). SeeThruEquity estimated a 12-month price target of $4.20 for the company.
Biotricity is an emerging medical technology company that is focused on preventative health solutions. The company concentrates on developing and delivering remote patient monitoring and connected health solutions for disease management and lifestyle improvement in both diagnostic and post-diagnostic settings. With an eye toward putting health management into the hands of the patient, the company uses proprietary technology to develop cutting-edge solutions that empower the self-management of critical and chronic conditions and ease the rising burden on the health care system.
At present, Biotricity is directing its lead product, Bioflux, toward the monitoring of cardiovascular disease (CVD). With Bioflux, the company has designed a wearable mobile device and echocardiogram (ECG) system that boosts a doctor’s ability to monitor and diagnose CVD. Bioflux allows doctors to detect CVD or coronary heart diseases while also serving as an ambulatory monitor capable of identifying arrhythmias; acting as a remote mobile cardiac telemetry diagnostic monitor; and communicating ECG data via a built-in cellular radio in real-time. As a result, Biotricity’s management team is pursuing a 510(k) regulatory pathway for Bioflux and expecting to receive clearance to market the device in the first quarter of 2017.
In the future, the company intends to look beyond Bioflux at other sectors that present opportunities for long-term growth. For example, Biotricity intends to launch its Biolife health and lifestyle solution for the chronic illness side of the consumer market in 2017, aiming it at those individuals with high risks of CVD or who are already diagnosed with it. The Biolife solution consists of a clinical-grade heart monitor that reads ECG data or heart rhythms, as well as respiration, calories, temperature, physical activity and more. Additionally, the company plans to introduce products that target sleep apnea, fetal ECG monitoring, and diabetes monitoring to the wider healthcare market, as these three medical areas represent multi-billion dollar opportunities, if the company successfully executes its plan.
For more information, visit www.Biotricity.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, December 22, 2016
CytoDyn Inc. (CYDY) Announces Engagement of NetworkNewsWire for Corporate Communications Solutions
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection and other diseases, announced this morning that it has engaged the expertise of NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility via social media and a rapidly expanding distribution network of well over 5,000 key syndication outlets.
“Maintaining strong communication with CytoDyn shareholders is highly important as we pursue regulatory approval of PRO 140, our leading monoclonal antibody for HIV infection,” Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, stated in this morning’s news release. “As we focus on our ongoing Phase 3 clinical trial with PRO 140, NNW will work behind the scenes and use its vast network to keep existing and potential investors up-to-date on our progress.”
As part of the Client-Partner relationship with CytoDyn, NNW will leverage its investor-based Brand Network of partners, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“Though tremendously invaluable, communication strategies are an often overlooked aspect of business for many biotech and biopharma companies,” Sherri Franklin, director of Content Marketing for NNW, added in the release. “CytoDyn, however, is taking a proactive approach in making sure the investment community is aware of its progress. We look forward to working with this exciting company as it addresses a significant global concern and advances its clinical development of monoclonal antibodies for treatment of HIV infection.”
For more information, visit www.CytoDyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“Maintaining strong communication with CytoDyn shareholders is highly important as we pursue regulatory approval of PRO 140, our leading monoclonal antibody for HIV infection,” Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, stated in this morning’s news release. “As we focus on our ongoing Phase 3 clinical trial with PRO 140, NNW will work behind the scenes and use its vast network to keep existing and potential investors up-to-date on our progress.”
As part of the Client-Partner relationship with CytoDyn, NNW will leverage its investor-based Brand Network of partners, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“Though tremendously invaluable, communication strategies are an often overlooked aspect of business for many biotech and biopharma companies,” Sherri Franklin, director of Content Marketing for NNW, added in the release. “CytoDyn, however, is taking a proactive approach in making sure the investment community is aware of its progress. We look forward to working with this exciting company as it addresses a significant global concern and advances its clinical development of monoclonal antibodies for treatment of HIV infection.”
For more information, visit www.CytoDyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
QualityStocks Keeps Investors Abreast of Small-cap Market’s Latest and Greatest
There’s a barrage of financial information available at any given moment – while it initially sounds great, investors need a quick, clear-cut method to dig through the madness to find their next great investment opportunity. QualityStocks keeps investors up-to-date on everything related to the small-cap and micro-cap markets by offering several ways to filter through the information to easily find the material needed.
The QualityStocks Blog is updated daily; investors can read about leading players in the small-cap and micro-cap markets and discover emerging companies flying under the radar along the way. We’re not just committed to highlighting rising stocks; we’re also going to tip you off to ones you may not have noticed before.
With all the “hottest” picks and recommendations available in the investment world, how do you decide which stocks are worth a second look and which ones you need to avoid? At QualityStocks, we collate hundreds of investment newsletters into ONE daily newsletter, “The QualityStocks Daily,” which lists all the latest and most talked about stock picks of the day. We organize the data so you have the most up-to-date information delivered right to your inbox.
The QualityStocks Message Board is one of the most highly regulated, no-nonsense forums online today; an uncommon haven of highly relevant, SPAM-free investor interaction. Avoid the typical message board pumping, bashing, advertising or malicious posts – the QualityStocks Message Board is market interaction at its finest.
With QualityStocks you will:
• Stay on top of momentum trading opportunities!
• Discover high-performance winning stock picks from ONE newsletter source!
• Watch investment newsletters to see who is making the best recommendations!
• Keep track of new investment newsletter sources as they are published!
• Track stock picks by exchange and by price trading point!
• Protect your e-mail inbox from unwanted spam by unsolicited commercial offers!
For more information, visit www.QualityStocks.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The QualityStocks Blog is updated daily; investors can read about leading players in the small-cap and micro-cap markets and discover emerging companies flying under the radar along the way. We’re not just committed to highlighting rising stocks; we’re also going to tip you off to ones you may not have noticed before.
With all the “hottest” picks and recommendations available in the investment world, how do you decide which stocks are worth a second look and which ones you need to avoid? At QualityStocks, we collate hundreds of investment newsletters into ONE daily newsletter, “The QualityStocks Daily,” which lists all the latest and most talked about stock picks of the day. We organize the data so you have the most up-to-date information delivered right to your inbox.
The QualityStocks Message Board is one of the most highly regulated, no-nonsense forums online today; an uncommon haven of highly relevant, SPAM-free investor interaction. Avoid the typical message board pumping, bashing, advertising or malicious posts – the QualityStocks Message Board is market interaction at its finest.
With QualityStocks you will:
• Stay on top of momentum trading opportunities!
• Discover high-performance winning stock picks from ONE newsletter source!
• Watch investment newsletters to see who is making the best recommendations!
• Keep track of new investment newsletter sources as they are published!
• Track stock picks by exchange and by price trading point!
• Protect your e-mail inbox from unwanted spam by unsolicited commercial offers!
For more information, visit www.QualityStocks.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, December 21, 2016
OurPet’s Company (OPCO), Growing 50% Faster than the Industry Rate, Is a Bargain Buy
In the world of value investing, not all that is gold glitters… like Ohio-based OurPet’s Company, for example. OurPet’s Company (OTCQX: OPCO) is a leading proprietary pet supply company that designs, produces, and markets a broad line of innovative, high-quality accessory and consumable pet products under the OurPets® and Pet Zone® brands in the U.S. and international markets. Its yearly revenues have been rising at a steady clip since its inception over 20 years ago and so, too, have its profits. Yet OPCO’s valuation is way below what you might expect. Could this be a case of investors eschewing value because they don’t like the packaging?
No, you may argue. Investors are rational. They make decisions that maximize utility. The rational investor will base his decision on expected returns. Yet, we know now that that is not entirely true. Despite our claims to be rational, we demonstrate a great deal of ‘risk aversion’. We don’t like to lose. We will play it safe because the pain of losing a dollar is greater than the pleasure of finding one.
However, if losing money causes pain, why then do we gamble? Several explanations have been offered. It may be that gamblers are a naughty subset of the population who, unlike their more mature brethren, are decidedly irrational. It may be that our attitudes to risk change with mood. On days when our world looks bright, we are prepared to take more risks than when things don’t look so good. Perhaps, gambling is seen more as entertainment. We would like to win, but if we don’t, at least we had a good time. Or is it because of all the idiosyncrasies that make us human? It isn’t rational, for example, to sacrifice your life to save a stranger. Yet, as ‘The Man in the Water’ (http://dtn.fm/t6Lrk) has shown us, we each have the capacity to do just that.
So investors like glamour. If we say we’re invested early in Facebook or Google, wouldn’t we be regarded as savants? Isn’t that the way Warren Buffet works?
Irony aside, Buffet’s success is based on ‘value investing’. He famously said, “Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.” True value investing means picking up a bargain, companies whose stock prices don’t reflect their fundamental worth. In other words, buy it when it’s on sale.
OPCO is one such company. It prides itself on adaptability. CEO Dr. Steve Tsengas has remarked that one of the main rationales behind the founding of OurPet’s Company in 1994 was the lack of innovation in the pet industry at that time. In fact, so intent on the knowledge-based aspect of the enterprise were its co-founders, Dr. Steve Tsengas and Dean Tsengas, that they decided to focus on generating new and improved solutions for pet owners and ways of getting product to market rather than manufacturing. So, on the one hand, OurPet’s Company concentrates on innovation and design, and, on the other, on marketing and distributing its product line.
The company is focused on high-growth categories in the non-food segment of the pet products market. Healthy feeding/storage systems (http://dtn.fm/3GFrs) represent a $100 million a year market. Feline waste and odor control (http://dtn.fm/3eqBo) is a $250 million a year market. And the interactive cat and dog toys/accessories segment (http://dtn.fm/n4VDL) is a whopping $1 billion a year market.
OPCO has been growing 50 percent faster than the industry rate. With a P/E ratio that has ranged between 12.5 and 14.5, OPCO is definitely a bargain buy.
For more information, visit the company’s website at www.OurPets.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No, you may argue. Investors are rational. They make decisions that maximize utility. The rational investor will base his decision on expected returns. Yet, we know now that that is not entirely true. Despite our claims to be rational, we demonstrate a great deal of ‘risk aversion’. We don’t like to lose. We will play it safe because the pain of losing a dollar is greater than the pleasure of finding one.
However, if losing money causes pain, why then do we gamble? Several explanations have been offered. It may be that gamblers are a naughty subset of the population who, unlike their more mature brethren, are decidedly irrational. It may be that our attitudes to risk change with mood. On days when our world looks bright, we are prepared to take more risks than when things don’t look so good. Perhaps, gambling is seen more as entertainment. We would like to win, but if we don’t, at least we had a good time. Or is it because of all the idiosyncrasies that make us human? It isn’t rational, for example, to sacrifice your life to save a stranger. Yet, as ‘The Man in the Water’ (http://dtn.fm/t6Lrk) has shown us, we each have the capacity to do just that.
So investors like glamour. If we say we’re invested early in Facebook or Google, wouldn’t we be regarded as savants? Isn’t that the way Warren Buffet works?
Irony aside, Buffet’s success is based on ‘value investing’. He famously said, “Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.” True value investing means picking up a bargain, companies whose stock prices don’t reflect their fundamental worth. In other words, buy it when it’s on sale.
OPCO is one such company. It prides itself on adaptability. CEO Dr. Steve Tsengas has remarked that one of the main rationales behind the founding of OurPet’s Company in 1994 was the lack of innovation in the pet industry at that time. In fact, so intent on the knowledge-based aspect of the enterprise were its co-founders, Dr. Steve Tsengas and Dean Tsengas, that they decided to focus on generating new and improved solutions for pet owners and ways of getting product to market rather than manufacturing. So, on the one hand, OurPet’s Company concentrates on innovation and design, and, on the other, on marketing and distributing its product line.
The company is focused on high-growth categories in the non-food segment of the pet products market. Healthy feeding/storage systems (http://dtn.fm/3GFrs) represent a $100 million a year market. Feline waste and odor control (http://dtn.fm/3eqBo) is a $250 million a year market. And the interactive cat and dog toys/accessories segment (http://dtn.fm/n4VDL) is a whopping $1 billion a year market.
OPCO has been growing 50 percent faster than the industry rate. With a P/E ratio that has ranged between 12.5 and 14.5, OPCO is definitely a bargain buy.
For more information, visit the company’s website at www.OurPets.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, December 20, 2016
CytoDyn Inc. (CYDY) Targets HIV as its Lead Product, PRO 140, Enters Phase 3 Clinical Development
CytoDyn Inc. (OTCQB: CYDY) is entering a Phase 3 clinical trial with its leading product candidate, PRO 140, and the Washington-based biotech is showing a lot of progress nearing major milestones. PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that work by blocking the entry of the human immunodeficiency virus (HIV) to healthy cells. PRO 140 is presently at the Phase 3 clinical trial stage. For the millions worldwide with HIV/AIDS, PRO 140 could offer the promise of a more robust bodyguard from further viral insult with potentially fewer side effects and hardly any toxicity.
HIV, like many other dangerous viruses, has a formidable ability to reproduce itself. The virus will invade an immune system cell and employ that cell’s reproductive machinery to make copies of itself, often killing the host cell in the process. New viral particles then emerge from the host and go on to infect other cells.
Many of the current AIDS therapies slow HIV replication by inhibiting viral enzymes within cells already affected by HIV. However, a new class of drugs, known as viral entry inhibitors, is designed to protect healthy cells from HIV infection by blocking early steps in the viral life cycle.
HIV infection occurs when the virus gains entry to two ‘doorways’ or receptors on the cell surface. These are the CD4 receptor and the co-receptor CCR5. The GP120 protein of HIV first attaches to the CD4 receptor on the cell membrane and then is able to bind to the co-receptor CCR5. At that point, the chips are down. The membranes of the virus and the immune cell fuse, and genetic material from HIV enters the cell.
PRO 140 works by attaching to the same portion of the CCR5 co-receptor to which HIV normally binds. The PRO 140 monoclonal antibodies physically block the HIV from attaching to the CCR5 co-receptor and arrest the completion of the second step in the entry process. The HIV is, consequently, rendered ineffective.
The approach taken by PRO 140 has a distinct advantage over other therapies. The normal function of CCR5 is to bind chemokines, molecules that regulate inflammation. Other HIV drugs that target CCR5 interact with the pocket of the receptor and thereby inhibit binding of both HIV and chemokines, which may have a number of adverse consequences because of the disruption of the chemokine inflammatory response. However, PRO 140 blocks HIV yet permits normal chemokine binding leading to potentially less side effects.
Early clinical testing indicates that PRO 140’s half-life contributes to the masking of CCR5 receptors for up to two months. Thus, infrequent dosing with PRO 140 may be possible compared to small molecule drugs, which require daily dosing.
In addition, being an antibody and not a synthetic drug means that PRO 140 will, most likely, have fewer issues with toxicity. Previous short and long-term trials have shown that PRO 140 is less likely to induce the development of resistant viruses.
Earlier this month, CytoDyn Inc. announced that several patients had been treated in the first single-agent maintenance therapy, Phase 3 (instead of today’s standard of care of at least three agents) in virally suppressed subjects with HIV. PRO 140 is considered one of the most advanced experimental monoclonal antibodies for HIV treatment and has been used in more than 140 HIV-infected patients in placebo controlled and open label FDA-approved clinical trials. The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and being designated a “fast track” product candidate by the FDA.
CytoDyn is a biotechnology company focused on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection.
For more information, visit www.CytoDyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
HIV, like many other dangerous viruses, has a formidable ability to reproduce itself. The virus will invade an immune system cell and employ that cell’s reproductive machinery to make copies of itself, often killing the host cell in the process. New viral particles then emerge from the host and go on to infect other cells.
Many of the current AIDS therapies slow HIV replication by inhibiting viral enzymes within cells already affected by HIV. However, a new class of drugs, known as viral entry inhibitors, is designed to protect healthy cells from HIV infection by blocking early steps in the viral life cycle.
HIV infection occurs when the virus gains entry to two ‘doorways’ or receptors on the cell surface. These are the CD4 receptor and the co-receptor CCR5. The GP120 protein of HIV first attaches to the CD4 receptor on the cell membrane and then is able to bind to the co-receptor CCR5. At that point, the chips are down. The membranes of the virus and the immune cell fuse, and genetic material from HIV enters the cell.
PRO 140 works by attaching to the same portion of the CCR5 co-receptor to which HIV normally binds. The PRO 140 monoclonal antibodies physically block the HIV from attaching to the CCR5 co-receptor and arrest the completion of the second step in the entry process. The HIV is, consequently, rendered ineffective.
The approach taken by PRO 140 has a distinct advantage over other therapies. The normal function of CCR5 is to bind chemokines, molecules that regulate inflammation. Other HIV drugs that target CCR5 interact with the pocket of the receptor and thereby inhibit binding of both HIV and chemokines, which may have a number of adverse consequences because of the disruption of the chemokine inflammatory response. However, PRO 140 blocks HIV yet permits normal chemokine binding leading to potentially less side effects.
Early clinical testing indicates that PRO 140’s half-life contributes to the masking of CCR5 receptors for up to two months. Thus, infrequent dosing with PRO 140 may be possible compared to small molecule drugs, which require daily dosing.
In addition, being an antibody and not a synthetic drug means that PRO 140 will, most likely, have fewer issues with toxicity. Previous short and long-term trials have shown that PRO 140 is less likely to induce the development of resistant viruses.
Earlier this month, CytoDyn Inc. announced that several patients had been treated in the first single-agent maintenance therapy, Phase 3 (instead of today’s standard of care of at least three agents) in virally suppressed subjects with HIV. PRO 140 is considered one of the most advanced experimental monoclonal antibodies for HIV treatment and has been used in more than 140 HIV-infected patients in placebo controlled and open label FDA-approved clinical trials. The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and being designated a “fast track” product candidate by the FDA.
CytoDyn is a biotechnology company focused on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection.
For more information, visit www.CytoDyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, December 19, 2016
CytoDyn Inc. (CYDY) is “One to Watch”
CytoDyn Inc. (OTCQB: CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection.
Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn’s lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.
PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral infection. The candidate has been used in more than 200 HIV-infected patients in placebo-controlled and open label FDA-approved clinical trials; has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and is designated a “fast track” product candidate by the FDA.
The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially hardly any side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use. CytoDyn has received FDA clearance for and currently has two Phase 3 clinical trials underway. The company’s first Phase 3 trial is a pivotal trial with PRO 140 in combination with current standard-of-care antiretroviral therapy (ART) for highly treatment-experienced patients with HIV. This 25-week trial involves only 30 patients with a primary endpoint of just one week of efficacy and the company expects to report primary endpoint results as early as the first quarter of 2017.
The company’s other Phase 3 trial is with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. This multicenter, open-label trial is now enrolling 300 patients prequalified with CCR5-tropic HIV-1 infection who are clinically stable on standard-of-care highly active antiretroviral therapy (HAART). The objective of the trial is to assess the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Patients enrolled in the trial will be shifted from daily HAART regimens to weekly PRO 140 subcutaneous injections for 48 weeks. This trial protocol is nearly a duplicate of the Phase 2b monotherapy trial, which is ongoing with an extension study that supports a group of patients who have maintained viral suppression for over two years and is continuing.
Additionally, the company has underway a Phase 2 trial to evaluate PRO 140 for Graft vs. Host Disease (GvHD) in a 100-day study involving 60 patients. GvHD is a life-threatening complication for cancer patients undergoing stem cell transplants. This trial will evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem-cell transplantation.
CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more. Additionally, CytoDyn has established relationships with world-class HIV experts who advise on the company’s trial designs.
For more information, visit www.CytoDyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn’s lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.
PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral infection. The candidate has been used in more than 200 HIV-infected patients in placebo-controlled and open label FDA-approved clinical trials; has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and is designated a “fast track” product candidate by the FDA.
The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially hardly any side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use. CytoDyn has received FDA clearance for and currently has two Phase 3 clinical trials underway. The company’s first Phase 3 trial is a pivotal trial with PRO 140 in combination with current standard-of-care antiretroviral therapy (ART) for highly treatment-experienced patients with HIV. This 25-week trial involves only 30 patients with a primary endpoint of just one week of efficacy and the company expects to report primary endpoint results as early as the first quarter of 2017.
The company’s other Phase 3 trial is with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. This multicenter, open-label trial is now enrolling 300 patients prequalified with CCR5-tropic HIV-1 infection who are clinically stable on standard-of-care highly active antiretroviral therapy (HAART). The objective of the trial is to assess the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Patients enrolled in the trial will be shifted from daily HAART regimens to weekly PRO 140 subcutaneous injections for 48 weeks. This trial protocol is nearly a duplicate of the Phase 2b monotherapy trial, which is ongoing with an extension study that supports a group of patients who have maintained viral suppression for over two years and is continuing.
Additionally, the company has underway a Phase 2 trial to evaluate PRO 140 for Graft vs. Host Disease (GvHD) in a 100-day study involving 60 patients. GvHD is a life-threatening complication for cancer patients undergoing stem cell transplants. This trial will evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem-cell transplantation.
CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more. Additionally, CytoDyn has established relationships with world-class HIV experts who advise on the company’s trial designs.
For more information, visit www.CytoDyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Rennova Health, Inc. (NASDAQ: RNVA) Creating the Next Generation of Health Care
Rennova Health, Inc. (NASDAQ: RNVA, RNVAX), a vertically integrated public holding company serving the health care sector, focuses on offering comprehensive single-source solutions to health care providers ranging from diagnostic laboratory testing to technology solutions, revenue cycle management and financial and billing services. With a declared goal of creating efficient, innovative and empowering solutions, the company is dedicated to putting the needs of health care providers and their patients at the center of everything it does.
The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting better treatment outcomes, increasing patient care efficiency and optimizing revenue streams. Available individually or as a package, these industry-leading supportive software and diagnostics solutions and services work together to empower customers and help shape the next generation of health care.
The diagnostics testing solutions include highly complex clinical, toxicology and esoteric laboratory services, offered via Rennova Health’s subsidiary, Medytox Diagnostics, and its five labs located strategically across the country. These laboratories offer specialized services of urine drug testing for prescription medication, abuse drugs and pain medication, as well as toxicology, clinical chemistry, hematology, serology, immunology and esoteric testing services such as neurotransmitter tests. The testing and sampling process uses the company’s proprietary StableSpot™ methodology.
The company currently has an active customer base with 139 clients and possesses Medicaid licenses in a total of 28 states. Also part of its clinical lab operations segment, Rennova Health recently initiated the acquisition of various assets of a rural clinical access hospital that filed for Chapter 11 bankruptcy. The acquisition process is to be completed early next year, with the hospital and its laboratory likely back in operation in the third quarter of 2017. Another major acquisition the company plans is that of Genomics, Inc., a biomedical diagnostics company that offers personalized medicine via DNA-guided management. Genomics uses a patented combination of genes and a proprietary platform that correlates gene and physiological variability to come up with ideal medication for pain, diabetes, mental illness and heart disease.
Another essential component of Rennova’s comprehensive solutions offering is health care technology. The company’s integrated software solutions include both specialized applications and simplified technologies for electronic health records, an advanced laboratory information management system and a reporting application designed to help streamline diagnostic laboratory testing, as well as information solutions for precision oncology. The company launched an electronic health records service in the substance abuse sector in the last quarter of 2015 and currently has approximately 100 EHR clients across all verticals.
As for revenue cycle management services, Rennova’s in-house medical billing services solution, Medical Billing Choices, offers a customer-centered workflow designed to minimize errors, streamline customers’ billing cycles and maximize cash flow by expediting tasks such as insurance eligibility checks, claims submissions, and payment collecting. The company launched a specialized medical billing division for substance abuse facilities in the third quarter of the year and currently has approximately 20 facilities as customers.
Rennova also offers financial service solutions to health care providers, designed to help them maintain positive cash flows and overcome any income gaps cause by slow-to-pay customers. From special loans collaterized by accounts receivable to acquisitions of qualifying accounts receivable at a discounted rate, the company offers a wealth of financial solutions tailored to every customer.
For 2017 as well as long term, Rennova Health has plans to create and maintain a sustainable relationship with its customers, to grow revenue and provide added value to its shareholders by increasing and diversifying its diagnostics business, offering improved supportive software solutions and exploring new ways to improve provider and patient outcomes for various diagnostics, including cancer and diabetes. The company’s main target markets at the moment are pain management and drug and alcohol rehabilitation.
For more information, visit www.RennovaHealth.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting better treatment outcomes, increasing patient care efficiency and optimizing revenue streams. Available individually or as a package, these industry-leading supportive software and diagnostics solutions and services work together to empower customers and help shape the next generation of health care.
The diagnostics testing solutions include highly complex clinical, toxicology and esoteric laboratory services, offered via Rennova Health’s subsidiary, Medytox Diagnostics, and its five labs located strategically across the country. These laboratories offer specialized services of urine drug testing for prescription medication, abuse drugs and pain medication, as well as toxicology, clinical chemistry, hematology, serology, immunology and esoteric testing services such as neurotransmitter tests. The testing and sampling process uses the company’s proprietary StableSpot™ methodology.
The company currently has an active customer base with 139 clients and possesses Medicaid licenses in a total of 28 states. Also part of its clinical lab operations segment, Rennova Health recently initiated the acquisition of various assets of a rural clinical access hospital that filed for Chapter 11 bankruptcy. The acquisition process is to be completed early next year, with the hospital and its laboratory likely back in operation in the third quarter of 2017. Another major acquisition the company plans is that of Genomics, Inc., a biomedical diagnostics company that offers personalized medicine via DNA-guided management. Genomics uses a patented combination of genes and a proprietary platform that correlates gene and physiological variability to come up with ideal medication for pain, diabetes, mental illness and heart disease.
Another essential component of Rennova’s comprehensive solutions offering is health care technology. The company’s integrated software solutions include both specialized applications and simplified technologies for electronic health records, an advanced laboratory information management system and a reporting application designed to help streamline diagnostic laboratory testing, as well as information solutions for precision oncology. The company launched an electronic health records service in the substance abuse sector in the last quarter of 2015 and currently has approximately 100 EHR clients across all verticals.
As for revenue cycle management services, Rennova’s in-house medical billing services solution, Medical Billing Choices, offers a customer-centered workflow designed to minimize errors, streamline customers’ billing cycles and maximize cash flow by expediting tasks such as insurance eligibility checks, claims submissions, and payment collecting. The company launched a specialized medical billing division for substance abuse facilities in the third quarter of the year and currently has approximately 20 facilities as customers.
Rennova also offers financial service solutions to health care providers, designed to help them maintain positive cash flows and overcome any income gaps cause by slow-to-pay customers. From special loans collaterized by accounts receivable to acquisitions of qualifying accounts receivable at a discounted rate, the company offers a wealth of financial solutions tailored to every customer.
For 2017 as well as long term, Rennova Health has plans to create and maintain a sustainable relationship with its customers, to grow revenue and provide added value to its shareholders by increasing and diversifying its diagnostics business, offering improved supportive software solutions and exploring new ways to improve provider and patient outcomes for various diagnostics, including cancer and diabetes. The company’s main target markets at the moment are pain management and drug and alcohol rehabilitation.
For more information, visit www.RennovaHealth.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Friday, December 16, 2016
Singlepoint, Inc. (SING) CEO Comments on Company’s Above-Average Volume in Interview on MoneyTV with Donald Baillargeon
Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.
To view this week’s program, visit www.MoneyTV.net
In the interview, Greg Lambrecht, chief executive officer of Singlepoint, commented on the recent movement of the company’s stock, which has recorded above-average volume throughout much of the past two months. On November 4, in particular, Singlepoint’s volume climbed to 22.6 million. For comparison, the company’s average 30-day volume prior to this spike was roughly 4.35 million, according to OTC Markets. Singlepoint’s price per share recorded a similar spike in mid-November.
“We’ve had enormous response from funders, not only in New York but across the country, that are interested in investing in Singlepoint and also interested in helping us with some of our acquisitions,” Lambrecht stated in reference to the company’s recent volume. “We are in the process of looking at a couple of different funding deals and a couple of different acquisitions. It’s a very exciting time right now.”
One driver behind rising investor interest surrounding Singlepoint could be its ongoing forays into the legalized cannabis industry. In early November, the company announced plans to reawaken its SingleSeed subsidiary in order to gain access to the domestic cannabis market, which is projected to climb to $50 billion by 2026, according to data from financial services firm Cowen and Co. In line with these efforts, Singlepoint has recently turned its attention toward broadening its presence in the nation’s cannabis markets ahead of an expected resolution to the industry’s long-standing banking problem.
“One of the things we’re doing, we’re spending some money on really making our SingleSeed website live. That’s SingleSeed.com, and it is specifically set up for dispensaries,” Lambrecht told host Donald Baillargeon. “We’re turning that on to allow people to go in and sign one of our agreements and start to get our text message marketing, which is legal now, and sign up to get a terminal when it’s opened up.”
Lambrecht concluded the MoneyTV interview by taking a look at the current regulatory environment surrounding the cannabis industry. With President-elect Donald Trump having previously suggested plans to leave the regulation of recreational marijuana in the hands of individual states, Lambrecht predicts that it’s only a matter of time before a decision is made to give legal cannabis operations access to financial institutions and electronic payment solutions.
“A congressman from California has already written the Trump administration asking for a meeting,” Lambrecht concluded. “Basically, he’s saying, ‘Hey, California is opened up. These dispensaries need to have a bank account.’ So that, with Florida and Massachusetts, I think the pendulum has swung to where they’re going to let these dispensaries have bank accounts. When that happens, that’s going to be very exciting for Singlepoint.”
For more information, visit the company’s website at www.Singlepoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
To view this week’s program, visit www.MoneyTV.net
In the interview, Greg Lambrecht, chief executive officer of Singlepoint, commented on the recent movement of the company’s stock, which has recorded above-average volume throughout much of the past two months. On November 4, in particular, Singlepoint’s volume climbed to 22.6 million. For comparison, the company’s average 30-day volume prior to this spike was roughly 4.35 million, according to OTC Markets. Singlepoint’s price per share recorded a similar spike in mid-November.
“We’ve had enormous response from funders, not only in New York but across the country, that are interested in investing in Singlepoint and also interested in helping us with some of our acquisitions,” Lambrecht stated in reference to the company’s recent volume. “We are in the process of looking at a couple of different funding deals and a couple of different acquisitions. It’s a very exciting time right now.”
One driver behind rising investor interest surrounding Singlepoint could be its ongoing forays into the legalized cannabis industry. In early November, the company announced plans to reawaken its SingleSeed subsidiary in order to gain access to the domestic cannabis market, which is projected to climb to $50 billion by 2026, according to data from financial services firm Cowen and Co. In line with these efforts, Singlepoint has recently turned its attention toward broadening its presence in the nation’s cannabis markets ahead of an expected resolution to the industry’s long-standing banking problem.
“One of the things we’re doing, we’re spending some money on really making our SingleSeed website live. That’s SingleSeed.com, and it is specifically set up for dispensaries,” Lambrecht told host Donald Baillargeon. “We’re turning that on to allow people to go in and sign one of our agreements and start to get our text message marketing, which is legal now, and sign up to get a terminal when it’s opened up.”
Lambrecht concluded the MoneyTV interview by taking a look at the current regulatory environment surrounding the cannabis industry. With President-elect Donald Trump having previously suggested plans to leave the regulation of recreational marijuana in the hands of individual states, Lambrecht predicts that it’s only a matter of time before a decision is made to give legal cannabis operations access to financial institutions and electronic payment solutions.
“A congressman from California has already written the Trump administration asking for a meeting,” Lambrecht concluded. “Basically, he’s saying, ‘Hey, California is opened up. These dispensaries need to have a bank account.’ So that, with Florida and Massachusetts, I think the pendulum has swung to where they’re going to let these dispensaries have bank accounts. When that happens, that’s going to be very exciting for Singlepoint.”
For more information, visit the company’s website at www.Singlepoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
National Waste Management Holdings, Inc. (NWMH) Set to Capitalize on Untapped East Coast Opportunities
The increasing levels of solid waste generated in the U.S. each year is drawing attention from lawmakers, and strategies are being implemented on every level to address the issue. The U.S. Department of Agriculture (USDA) is taking steps (http://dtn.fm/tKM4H) to tap into the minds of state and local government entities, academic institutions, and private non-profit organizations by making available Solid Waste Management (SWM) and Technical Assistance and Training (TAT) grants to improve planning and management of solid waste sites in rural areas. In the business sector, National Waste Management Holdings (OTC: NWMH), a solid waste management company, has been steadily expanding its influence across the East Coast with an aggressive acquisition strategy that is bringing more and more facilities under its wing. The company’s comprehensive waste management approach includes an array of landfill disposal services, roll off containers for rental, and a line of recycled wood and garden mulch.
In a recent, exclusive audio interview (http://dtn.fm/7Yj2m) with NetworkNewsWire, a multifaceted financial news and publishing company, National Waste Management Holdings CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor spoke toward a few of the company’s 2017 acquisition goals. A recent article cites a paper shredding facility in New York as being under consideration, and that acquisition would open NWMH to a sizable market in the region. As it stands, NWMH already services residential and commercial customers in Upstate New York, as well as in its home state of Florida.
An article (http://dtn.fm/8tRw2) from the Proceedings of the National Academy of Sciences of the United States of America found, upon examining the world’s megacities, that New York exceeds the rest in solid waste production, both in absolute and per capita terms. In addition, despite Tokyo being the largest megacity by population, New York surpasses it in terms of energy consumption of both transportation fuels and heating/industrial fuels. The article also states that New York consumes the energy of approximately two megacities; the equivalent of approximately one supertanker every 1.5 days. Interestingly, statistics in the 2014 Tables and Figures (http://dtn.fm/iWhx3) published by the EPA last month show that the Northeast more than doubles the rest of the nation in terms of municipal waste-to-energy capacity, with nearly 800 tons/day throughput per million people. Resource recovery facilities can turn solid waste into vital energy. One such facility, for example, is the Essex County Resource Recovery Facility that processed 2,800 tons of municipal solid waste per day in 2012 between its two generators, producing approximately 65 megawatts of energy.
While the Northeast led in terms of waste-to-energy capacity as well as estimated MRF throughput in 2014, it had, by far, the least number of landfills in the U.S., per the EPA report, potentially signifying a largely untapped market. SaveOnEnergy.com notes (http://dtn.fm/IebN2) that New York is the largest giver of trash to Ohio, accounting for nearly 32 percent of the state’s out-of-state total, with New Jersey coming in close behind. National Waste Management Holding’s initial acquisition strategies on the East Coast are part of the company’s larger objective of national expansion.
For more information, visit the company’s website at www.nationalwastemgmt.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
In a recent, exclusive audio interview (http://dtn.fm/7Yj2m) with NetworkNewsWire, a multifaceted financial news and publishing company, National Waste Management Holdings CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor spoke toward a few of the company’s 2017 acquisition goals. A recent article cites a paper shredding facility in New York as being under consideration, and that acquisition would open NWMH to a sizable market in the region. As it stands, NWMH already services residential and commercial customers in Upstate New York, as well as in its home state of Florida.
An article (http://dtn.fm/8tRw2) from the Proceedings of the National Academy of Sciences of the United States of America found, upon examining the world’s megacities, that New York exceeds the rest in solid waste production, both in absolute and per capita terms. In addition, despite Tokyo being the largest megacity by population, New York surpasses it in terms of energy consumption of both transportation fuels and heating/industrial fuels. The article also states that New York consumes the energy of approximately two megacities; the equivalent of approximately one supertanker every 1.5 days. Interestingly, statistics in the 2014 Tables and Figures (http://dtn.fm/iWhx3) published by the EPA last month show that the Northeast more than doubles the rest of the nation in terms of municipal waste-to-energy capacity, with nearly 800 tons/day throughput per million people. Resource recovery facilities can turn solid waste into vital energy. One such facility, for example, is the Essex County Resource Recovery Facility that processed 2,800 tons of municipal solid waste per day in 2012 between its two generators, producing approximately 65 megawatts of energy.
While the Northeast led in terms of waste-to-energy capacity as well as estimated MRF throughput in 2014, it had, by far, the least number of landfills in the U.S., per the EPA report, potentially signifying a largely untapped market. SaveOnEnergy.com notes (http://dtn.fm/IebN2) that New York is the largest giver of trash to Ohio, accounting for nearly 32 percent of the state’s out-of-state total, with New Jersey coming in close behind. National Waste Management Holding’s initial acquisition strategies on the East Coast are part of the company’s larger objective of national expansion.
For more information, visit the company’s website at www.nationalwastemgmt.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
PharmaCyte Biotech, Inc. (PMCB) Pre-IND Meeting with FDA Makes ATM Funding Possible
For California-based PharmaCyte Biotech, Inc. (OTCQB: PMCB), a light at the end of the pipeline tunnel has become visible as one piece of good news follows another. The approval by the FDA to entertain a Pre-Investigational New Drug (Pre-IND) submission from the company sent PMCB stock soaring to triple its pre-approval value. The resulting market cap made PharmaCyte ‘primarily eligible’ to register securities for sale in an at-the-market (ATM) offering, which it now plans to do through Chardan Capital.
To make an ATM offering requires that the issuer be eligible, on a primary basis, to use a shelf registration statement on Form S-3. The Form S-3 filing initiates an equity distribution program under which, from time to time, ATM offerings can be made. Each ATM offering is a drawdown from the related shelf registration securities offering.
ATM offerings have a number of advantages. They typically cost less than traditional follow-on offerings, particularly since they are executed without high profile, expensive road shows. They also give an issuer the flexibility to determine the timing and size of any share sale, while allowing shares to ‘trickle’ into the market in a way that does not adversely affect the stock price.
PharmaCyte is now primarily eligible to use Form S-3 to offer securities, on its own behalf, for cash on an unlimited basis in ATM offerings, since the aggregate market value of its voting and non-voting common equity held by non-affiliates (i.e., the public float) is at least $75 million. The company intends to use funds received from the ATM offerings to advance the clinical trial process of its signature live-cell encapsulation technology, Cell-in-a-Box®.
PharmaCyte will be submitting a full Pre-IND package of information to the FDA that will set out essential elements of its planned Investigational New Drug (IND) application. After which, the FDA will review PharmaCyte’s manufacturing, preclinical pharmacology and toxicology, and clinical trial plans for the company’s therapy to treat locally advanced pancreatic cancer (LAPC). On successful completion of the review, PharmaCyte will be able to proceed with enrolment of the first clinical trial.
PharmaCyte’s clinical trial for LAPC is designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® and gemcitabine. The trial will be open-label and multi-site in nature, with sites in the U.S. and Europe. Patients with LAPC will be randomized equally into two groups. One group will receive gemcitabine chemotherapy alone, and the other will receive PharmaCyte’s pancreatic cancer therapy. In addition to comparing the anticancer activity and safety of the two therapies, a major aspect of the trial will be to determine if, and how well, PharmaCyte’s therapy can shrink inoperable tumors so that they may become operable.
To work on its novel technology, Cell-in-a-Box®, PharmaCyte has assembled a respected team of oncologists that includes leading pancreatic cancer expert Dr. Daniel Von Hoff from Translational Drug Development (TD2), Dr. Manuel Hidalgo from Harvard Medical School, and Dr. Matthias Löhr from the Karolinska Institute in Stockholm, Sweden.
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. The Cell-in-a-Box® therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or anti-carcinogenic form.
These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to the location of the implanted encapsulated cells.
When the ifosfamide comes in contact with the encapsulated cells, they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This targeted chemotherapy has proven effective and safe to use in past clinical trials and results in no side effects.
For more information, visit www.pharmacyte.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Higher Price Target for Ocera Therapeutics (NASDAQ: OCRX) as Hepatic Encephalopathy Treatment Study Moves Forward
An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://dtn.fm/J0h97) released on December 8. The report reiterates a ‘Buy’ rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis.
The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead product candidate OCR-002 – an acute treatment for hepatic encephalopathy and hyperammonemia in patients with acute liver injury, acute liver failure and liver cirrhosis. The phase 2B study, called STOP-HE, will evaluate the safety, efficacy and tolerability of OCR-002 (Ornithine Phenylacetate) in hospitalized patients suffering from hepatic encephalopathy. The study enrolls a total of 230 subjects, which will be administered either OCR-002 or a placebo intravenously for five days. Based on their degree of liver impairment, patients will be given various doses of the drug, ranging from 10 to 20 grams over a 24-hour period.
Top-line data are due in the first quarter of 2017, which Aegis experts expect will be a share inflection point for the company. The study’s primary goal is to archive a meaningful clinical improvement in hepatic encephalopathy symptoms, so as to keep OCR-002 on track to potentially becoming a first-line, foundational therapy of choice for patients with this condition, on a market with significant unmet medical needs. Hepatic encephalopathy is a progressive complication of liver failure of cirrhosis which is marked by partial cognitive impairment including disorientation, confusion and impaired motor skills, while more severe forms can lead to coma and even the patient’s death.
According to the Agis report, there are currently only two hepatic encephalopathy products on the market, with others in development. Lactulose is a first-line therapy that has the largest market share at the moment, while Rifaximin is a second-line therapy. But Aegis analysts believe that OCR-002 has great potential and can take a significant market share, being unique in several respects: it has a unique mechanism of action as an ammonia scavenger, it is the only drug that can be administered intravenously and it has the potential to significantly shorten hospital stays.
If the phase 2B trial is successful, OCR-002 could reach approximately 170,000 patients that have hepatic encephalopathy and require hospitalization. Aegis analysts expect the therapy to achieve at least 22 percent market share and yield revenues of approximately $150 million. Ocera is also developing an oral formulation of the drug for chronic use, with the goal of preventing hepatic encephalopathy recurrences. The oral formulation was not included in the Aegis analysis, but it may indeed help provide an even larger share of the market.
As for potential risks for investors as identified in the report, these include typical manufacturing, commercialization, research and development, and regulatory risks that generally result from investing in pharmaceutical companies. The analysis also points out a series of specific risks of investing into Ocera, such as relying on the success of OCR-002, the company’s liquidity and high volatility.
For more information, visit the company’s website at www.ocerainc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead product candidate OCR-002 – an acute treatment for hepatic encephalopathy and hyperammonemia in patients with acute liver injury, acute liver failure and liver cirrhosis. The phase 2B study, called STOP-HE, will evaluate the safety, efficacy and tolerability of OCR-002 (Ornithine Phenylacetate) in hospitalized patients suffering from hepatic encephalopathy. The study enrolls a total of 230 subjects, which will be administered either OCR-002 or a placebo intravenously for five days. Based on their degree of liver impairment, patients will be given various doses of the drug, ranging from 10 to 20 grams over a 24-hour period.
Top-line data are due in the first quarter of 2017, which Aegis experts expect will be a share inflection point for the company. The study’s primary goal is to archive a meaningful clinical improvement in hepatic encephalopathy symptoms, so as to keep OCR-002 on track to potentially becoming a first-line, foundational therapy of choice for patients with this condition, on a market with significant unmet medical needs. Hepatic encephalopathy is a progressive complication of liver failure of cirrhosis which is marked by partial cognitive impairment including disorientation, confusion and impaired motor skills, while more severe forms can lead to coma and even the patient’s death.
According to the Agis report, there are currently only two hepatic encephalopathy products on the market, with others in development. Lactulose is a first-line therapy that has the largest market share at the moment, while Rifaximin is a second-line therapy. But Aegis analysts believe that OCR-002 has great potential and can take a significant market share, being unique in several respects: it has a unique mechanism of action as an ammonia scavenger, it is the only drug that can be administered intravenously and it has the potential to significantly shorten hospital stays.
If the phase 2B trial is successful, OCR-002 could reach approximately 170,000 patients that have hepatic encephalopathy and require hospitalization. Aegis analysts expect the therapy to achieve at least 22 percent market share and yield revenues of approximately $150 million. Ocera is also developing an oral formulation of the drug for chronic use, with the goal of preventing hepatic encephalopathy recurrences. The oral formulation was not included in the Aegis analysis, but it may indeed help provide an even larger share of the market.
As for potential risks for investors as identified in the report, these include typical manufacturing, commercialization, research and development, and regulatory risks that generally result from investing in pharmaceutical companies. The analysis also points out a series of specific risks of investing into Ocera, such as relying on the success of OCR-002, the company’s liquidity and high volatility.
For more information, visit the company’s website at www.ocerainc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, December 15, 2016
GainClients, Inc. (GCLT) Offering Buyers Simplified Home Search Tools with Comprehensive Results
U.S. home prices are going up steadily, having reached the highest peak in September after 2006’s real estate boom, a growth primarily driven by rising demand and a scarce inventory. The price hike came as a surprise to most real estate professionals, who expected a significant market slowdown in the last few months of 2016. While 2017 is likely to see more moderate growth, the market will continue to expand nonetheless, Realtor.com (http://dtn.fm/HdG6u) experts believe, as two of America’s largest generations – Millennials and baby boomers, are reaching a stage in their lives that typically motivates people to buy a home.
With this growing demand and a consistently smaller inventory, finding the right home will become more difficult than ever. GainClients, Inc. (OTC: GCLT), a leading provider of technology solutions for the real estate industry, aims at helping consumers look for and identify the right home for them via a comprehensive yet easy-to-use online search platform called GC HomeSearch (http://dtn.fm/AOI6o). The company’s declared goal is to offer simplified home search tools by providing buyers with a lot more information with a lot less, in an effort to make the home search process as easy and enjoyable as possible.
Through the online platform, buyers can get accurate and realistic knowledge of the homes they’re looking at, as well as the areas they’re located. This includes information such as home values, neighboring schools and services, demographic statistics, detailed property and neighborhood information, and more. Users can search as many properties as they want after registering for a free account. Search results can be sorted by city, state or zip code, and interesting properties can be saved for later viewing. Users can even find homes in their vicinity be entering the word ‘nearby’ in the search box.
The GC HomeSearch platform currently lists almost one million residential homes, which is encouraging given dwindling inventory numbers nationwide. According to Realtor.com statistics, the inventory of homes for sale in the top 100 metropolitan markets is going down at an average rate of 11 percent year after year, a trend that’s likely to continue next year as well.
The platform is the only GainClients service destined primarily to consumers, not real estate professionals, and was built with the intention of serving as a real estate community to all home buyers looking for their ideal property. For more in-depth information and backstage access to intelligent home buying and selling tools such as loan payment and rates calculators and closing cost estimates, users can link their GC HomeSearch account with the company’s flagship product, the GCard (http://dtn.fm/mQx7D) real estate networking system.
The GCard was designed with the primary purpose of helping real estate professionals connect and better communicate with their customers and other industry experts. This platform, accessible via web, mobile web, text message and smartphone app, gives real estate agents and lenders, as well as insurance agents, the means of providing consumers with the information they want when they want it. Professionals using this service are also able to network with each other, with the end goal of providing improved service to their clients.
For more information, visit the company’s website at www.gainclients.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
With this growing demand and a consistently smaller inventory, finding the right home will become more difficult than ever. GainClients, Inc. (OTC: GCLT), a leading provider of technology solutions for the real estate industry, aims at helping consumers look for and identify the right home for them via a comprehensive yet easy-to-use online search platform called GC HomeSearch (http://dtn.fm/AOI6o). The company’s declared goal is to offer simplified home search tools by providing buyers with a lot more information with a lot less, in an effort to make the home search process as easy and enjoyable as possible.
Through the online platform, buyers can get accurate and realistic knowledge of the homes they’re looking at, as well as the areas they’re located. This includes information such as home values, neighboring schools and services, demographic statistics, detailed property and neighborhood information, and more. Users can search as many properties as they want after registering for a free account. Search results can be sorted by city, state or zip code, and interesting properties can be saved for later viewing. Users can even find homes in their vicinity be entering the word ‘nearby’ in the search box.
The GC HomeSearch platform currently lists almost one million residential homes, which is encouraging given dwindling inventory numbers nationwide. According to Realtor.com statistics, the inventory of homes for sale in the top 100 metropolitan markets is going down at an average rate of 11 percent year after year, a trend that’s likely to continue next year as well.
The platform is the only GainClients service destined primarily to consumers, not real estate professionals, and was built with the intention of serving as a real estate community to all home buyers looking for their ideal property. For more in-depth information and backstage access to intelligent home buying and selling tools such as loan payment and rates calculators and closing cost estimates, users can link their GC HomeSearch account with the company’s flagship product, the GCard (http://dtn.fm/mQx7D) real estate networking system.
The GCard was designed with the primary purpose of helping real estate professionals connect and better communicate with their customers and other industry experts. This platform, accessible via web, mobile web, text message and smartphone app, gives real estate agents and lenders, as well as insurance agents, the means of providing consumers with the information they want when they want it. Professionals using this service are also able to network with each other, with the end goal of providing improved service to their clients.
For more information, visit the company’s website at www.gainclients.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
NuVasive, Inc.’s (NASDAQ: NUVA) Speed of Innovation and Absolute Responsiveness form the Backbone of its Rapid Growth
How does a start-up venture capital-backed company grow its revenues to nearly a billion dollars in the global spine industry in less than two decades? By developing a competitive advantage in Speed of Innovation® and Absolute Responsiveness®, two concepts that have made NuVasive, Inc. (NASDAQ: NUVA) the number three company in the spine industry with over 90 products in its portfolio, including lumbar, thoracic, and cervical applications; neuromonitoring services; and biologics solutions.
The global spinal implants and surgical devices market ‘is expected to reach USD 17.27 Billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021’, according to a press release from MarketsandMarkets (http://dtn.fm/uHV0W). Increasing longevity and the resulting larger elderly population means more spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, prolapsed intervertebral discs, and spinal stenosis. In addition, the development of minimally invasive surgical (MIS) procedures is leading to wider adoption of technologically advanced spinal implants.
MIS is NuVasive’s forte. The company is best known for developing the eXtreme Lateral Interbody Fusion® (XLIF) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of the company’s many innovative procedures, which have redefined spine surgery and opened doors to treat pathologies not previously treated with minimal disruption.
NuVasive has also developed a revolutionary nerve avoidance monitoring system (NVJJB™ /M5®) designed to help ensure nerve and spinal cord safety – this unique and advanced technology may help reduce the incidence of injury to neural elements during spinal procedures by providing real-time feedback and notifying surgeons immediately of any neurological insult. Additionally, NuVasive offers a portfolio of biologics products to help in the bone healing process.
A recent report from Aegis Capital (http://dtn.fm/H1sQC) suggests that NuVasive’s rapid growth is far from over. The company has been steadily paring manufacturing inefficiencies. As a consequence, gross profit has hovered around 75 percent. Other operating margin improvements are expected from economies of scope as the marketing offering expands and economies of scale form an increasingly larger international footprint. Aegis sees “900bp of operating improvements to come, which will continue to drive value.”
In a fast growing industry (2–3% p.a.), NuVasive, focused on developing minimally disruptive surgical products and procedures for the spine, is a fast growing company (2-3x faster than the overall market). The drivers of growth are its ‘expanding platform of offerings, adapting a holistic approach with regards to its sales effort, and increased Integrated Global Alignment (iGA) integration which allows better planning for deformity and saves cost.’
Alignment is one of three important factors to be considered when spine surgery is being contemplated. In cases of spondylolisthesis, for example, the first concern is usually decompression of the nerves to ease any pain or discomfort the patient may be experiencing. In many instances, this means removing the disc or other offending piece from the spine. The resulting space is, typically, filled by bone graft or a synthetic substance in a procedure known as lumbar interbody fusion (LIF). At this point, alignment procedures to straighten the spine may be implemented.
NuVasive, which has a presence in over 30 countries and employs more than 1,600 people globally, had revenues of $811 million in 2015. A 17 percent increase to $953 million is expected this year. Aegis has initiated coverage with a ‘Buy’ rating and a price target of $72.00. The stock, trading on the NASDAQ under the symbol NUVA, is currently around $67.00.
For more information, visit www.nuvasive.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The global spinal implants and surgical devices market ‘is expected to reach USD 17.27 Billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021’, according to a press release from MarketsandMarkets (http://dtn.fm/uHV0W). Increasing longevity and the resulting larger elderly population means more spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, prolapsed intervertebral discs, and spinal stenosis. In addition, the development of minimally invasive surgical (MIS) procedures is leading to wider adoption of technologically advanced spinal implants.
MIS is NuVasive’s forte. The company is best known for developing the eXtreme Lateral Interbody Fusion® (XLIF) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of the company’s many innovative procedures, which have redefined spine surgery and opened doors to treat pathologies not previously treated with minimal disruption.
NuVasive has also developed a revolutionary nerve avoidance monitoring system (NVJJB™ /M5®) designed to help ensure nerve and spinal cord safety – this unique and advanced technology may help reduce the incidence of injury to neural elements during spinal procedures by providing real-time feedback and notifying surgeons immediately of any neurological insult. Additionally, NuVasive offers a portfolio of biologics products to help in the bone healing process.
A recent report from Aegis Capital (http://dtn.fm/H1sQC) suggests that NuVasive’s rapid growth is far from over. The company has been steadily paring manufacturing inefficiencies. As a consequence, gross profit has hovered around 75 percent. Other operating margin improvements are expected from economies of scope as the marketing offering expands and economies of scale form an increasingly larger international footprint. Aegis sees “900bp of operating improvements to come, which will continue to drive value.”
In a fast growing industry (2–3% p.a.), NuVasive, focused on developing minimally disruptive surgical products and procedures for the spine, is a fast growing company (2-3x faster than the overall market). The drivers of growth are its ‘expanding platform of offerings, adapting a holistic approach with regards to its sales effort, and increased Integrated Global Alignment (iGA) integration which allows better planning for deformity and saves cost.’
Alignment is one of three important factors to be considered when spine surgery is being contemplated. In cases of spondylolisthesis, for example, the first concern is usually decompression of the nerves to ease any pain or discomfort the patient may be experiencing. In many instances, this means removing the disc or other offending piece from the spine. The resulting space is, typically, filled by bone graft or a synthetic substance in a procedure known as lumbar interbody fusion (LIF). At this point, alignment procedures to straighten the spine may be implemented.
NuVasive, which has a presence in over 30 countries and employs more than 1,600 people globally, had revenues of $811 million in 2015. A 17 percent increase to $953 million is expected this year. Aegis has initiated coverage with a ‘Buy’ rating and a price target of $72.00. The stock, trading on the NASDAQ under the symbol NUVA, is currently around $67.00.
For more information, visit www.nuvasive.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Nano Dimension Ltd. (NASDAQ: NNDM) Revolutionizing the Way Electronics are Made with 3D Printing
Nano Dimension Ltd. (NASDAQ: NNDM) is the holding company for Nano Dimension Technology Ltd., a company in the business of researching, developing, and manufacturing three-dimensional (3D) printers for printed circuit boards (PCBs). The company also develops nano ink materials and other products for electronics. NNDM has the vision of revolutionizing the way electronics are made with 3D printing by using 3D printers for multilayer PCBs, along with advanced nanotechnology-based conductive and dielectric inks.
Since the beginning of last year, Nano Dimension has won the Europe 2015 Award for Best Development in 3D Printing Equipment, the Gartner ‘Cool Vendor’ in 3D Printing 2016, and the TÜV SÜD Innovation 2016 award. NNDM is equipped with an experienced managerial team with a long background in the technology and 3D printing spaces, and the company is well-positioned to capitalize on the PCB prototyping industry, which is currently worth approximately $70 billion.
With the launch of its new DragonFly 2020 3D Printer to select beta customers in the U.S., Israel, and Germany, during the third and fourth quarters of this year, Nano Dimension Ltd. is expected to make sales on a more commercial level as early as 2017. The printer, which comes with specialized 3D software as well as conductive and dielectric inks, has now received attention from over 2,500 entities currently on the information waitlist. In addition, more than 30 NDAs have been signed to enable the collaboration and evaluation of this equipment.
With its new printer, Nano Dimension Ltd. plans to provide its clients with more advanced solutions than ever before while tapping into additional markets. Through the DragonFly 2020 3D Printer, Nano Dimension expects to meet the needs of additional market segments by offering faster solutions that print larger objects from a broader materials portfolio with functional inks.
According to The Daily Quint (http://dtn.fm/j5xiP), Nano Dimension has been the topic of conversation for several research analysts firms, receiving a consensus ‘Buy’ rating from five investment analysts with a consensus average price target of $12.60 per share. At close of market on December 13, 2016, the company’s shares were sold at an individual price of $6.05. NNDM’s market capitalization currently stands at $46.96 million.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Since the beginning of last year, Nano Dimension has won the Europe 2015 Award for Best Development in 3D Printing Equipment, the Gartner ‘Cool Vendor’ in 3D Printing 2016, and the TÜV SÜD Innovation 2016 award. NNDM is equipped with an experienced managerial team with a long background in the technology and 3D printing spaces, and the company is well-positioned to capitalize on the PCB prototyping industry, which is currently worth approximately $70 billion.
With the launch of its new DragonFly 2020 3D Printer to select beta customers in the U.S., Israel, and Germany, during the third and fourth quarters of this year, Nano Dimension Ltd. is expected to make sales on a more commercial level as early as 2017. The printer, which comes with specialized 3D software as well as conductive and dielectric inks, has now received attention from over 2,500 entities currently on the information waitlist. In addition, more than 30 NDAs have been signed to enable the collaboration and evaluation of this equipment.
With its new printer, Nano Dimension Ltd. plans to provide its clients with more advanced solutions than ever before while tapping into additional markets. Through the DragonFly 2020 3D Printer, Nano Dimension expects to meet the needs of additional market segments by offering faster solutions that print larger objects from a broader materials portfolio with functional inks.
According to The Daily Quint (http://dtn.fm/j5xiP), Nano Dimension has been the topic of conversation for several research analysts firms, receiving a consensus ‘Buy’ rating from five investment analysts with a consensus average price target of $12.60 per share. At close of market on December 13, 2016, the company’s shares were sold at an individual price of $6.05. NNDM’s market capitalization currently stands at $46.96 million.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
eXp World Holdings, Inc. (EXPI) Partners with MZ Group to Bolster Investor Relations and Outreach Efforts
Before the opening bell, eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for The Agent-Owned Cloud Brokerage®, announced its retention of MZ Group as its investor relations advisor. Moving forward, MZ Group will assist and advise EXPI regarding its ongoing communications with shareholders with the aim of strengthening the company’s public brand and broadening its investor base.
“We have chosen to partner with MZ Group to bolster our investor relations and outreach efforts during this time of rapid growth within our Company,” Glenn Sanford, founder, CEO and chairman of EXPI, stated in this morning’s news release. “While we have more than doubled in size over the past year due in large part to the dedicated efforts of our existing agent and broker network, we believe there is room for sustained growth as we continue to invest in our core infrastructure and agent and broker network.”
In recent months, EXPI, through the expansion of subsidiary eXp Realty, has recorded strong growth in terms of both market reach and financial results. As of its latest report, the company’s real estate brokerage division had more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. This marks an increase of nearly 155 percent from the beginning of 2016, when eXp Realty reported just 864 agents.
This market growth has translated into strong financial performance for EXPI in 2016, demonstrating the viability of the company’s current growth strategy. Last month, EXPI released its financial results for the third quarter of 2016, which included a 112 percent year-over-year increase in total revenues to $15.7 million. In the update, the company’s management team attributed this increase to eXp Realty’s growing sales agent base and the resulting rise to sales volume being generated by the real estate brokerage division.
EXPI’s share price has been on a similarly-promising upward trend throughout much of 2016. In January, the company’s PPS hovered around $0.84. By October, EXPI’s common stock climbed to a record high of more than $5.80 following the announcement of a new strategic partnership with Commissions, Inc., a leading provider of web-based real estate marketing and CRM software. The company’s stock is currently trading at around $4.35 per share.
News of EXPI’s retention of MZ Group comes just days after the company’s real estate brokerage division was recognized as a winner of the Oklahoma 2016 Top Workplaces Award by The Oklahoman newspaper. eXp Realty has previously received similar recognition in both Washington, D.C. and Atlanta for its commitment to creating a collaborative, engaging and rewarding work environment.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“We have chosen to partner with MZ Group to bolster our investor relations and outreach efforts during this time of rapid growth within our Company,” Glenn Sanford, founder, CEO and chairman of EXPI, stated in this morning’s news release. “While we have more than doubled in size over the past year due in large part to the dedicated efforts of our existing agent and broker network, we believe there is room for sustained growth as we continue to invest in our core infrastructure and agent and broker network.”
In recent months, EXPI, through the expansion of subsidiary eXp Realty, has recorded strong growth in terms of both market reach and financial results. As of its latest report, the company’s real estate brokerage division had more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. This marks an increase of nearly 155 percent from the beginning of 2016, when eXp Realty reported just 864 agents.
This market growth has translated into strong financial performance for EXPI in 2016, demonstrating the viability of the company’s current growth strategy. Last month, EXPI released its financial results for the third quarter of 2016, which included a 112 percent year-over-year increase in total revenues to $15.7 million. In the update, the company’s management team attributed this increase to eXp Realty’s growing sales agent base and the resulting rise to sales volume being generated by the real estate brokerage division.
EXPI’s share price has been on a similarly-promising upward trend throughout much of 2016. In January, the company’s PPS hovered around $0.84. By October, EXPI’s common stock climbed to a record high of more than $5.80 following the announcement of a new strategic partnership with Commissions, Inc., a leading provider of web-based real estate marketing and CRM software. The company’s stock is currently trading at around $4.35 per share.
News of EXPI’s retention of MZ Group comes just days after the company’s real estate brokerage division was recognized as a winner of the Oklahoma 2016 Top Workplaces Award by The Oklahoman newspaper. eXp Realty has previously received similar recognition in both Washington, D.C. and Atlanta for its commitment to creating a collaborative, engaging and rewarding work environment.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Hope for HIV Patients as Cytodyn Inc. (CYDY) Therapy Proves Efficacy during Clinical Trials
PRO 140, an innovative new therapy for HIV patients developed by Cytodyn Inc. (OTCQB: CYDY), is currently undergoing phase 3 clinical trials, having been administered to several patients, according to a company press release (http://dtn.fm/F40vr). No other details were provided about the initial results of phase 3 trials, but a separate report said actor Charlie Sheen is one of the subjects and that he has achieved undetectable viral load after taking PRO 140.
Sheen, who revealed his HIV status in November last year, has been a part of the study for eight months and is receiving weekly injections of the drug, the report said. The phase 3 study is looking into PRO 140’s safety and effectiveness in HIV patients and is being administered without any other HIV medication to determine whether it alone is enough to fight HIV and help subjects achieve an undetectable viral load.
Cytodyn, a biotech company that focuses on the development of innovative antibody therapies against the human immunodeficiency virus and other diseases, has not officially commented on the Daily Mail report. In a press release this week, however, it announced that several patients have already been treated with PRO 140 as part of the phase 3, multicenter clinical trial which will enroll a total of 300 subjects. All the patients included in the study have CCR5-tropic HIV-1 infection and are clinically stable, being on highly active antiretroviral therapy up to one week after the enrollment.
During the phase 3 trial, the subjects will receive only PRO 140 in the form of subcutaneous injections for 48 weeks to determine whether the product candidate is safe and efficient as a single-agent maintenance therapy for chronic suppression of HIV. PRO 140 is a fully humanized monoclonal antibody that specifically targets the CCR5 entry receptor on CD4 cells, which HIV targets and takes over. The proprietary therapy fights HIV by blocking this entry point and preventing the virus from infecting healthy cells.
CytoDyn CEO and President Nader Pourhassan, Ph.D. said his company expects the monotherapy trial to yield significant results and provide sufficient data to support further clinical and regulatory advancement of the treatment. He explained that the phase 3 trial is nearly a duplicate of the phase 2b trial that ended last year, with an additional objective of determining why some R5 patients are not responding to the therapy as well as others. Out of 15 subjects who continued the trial in the extension arm and received weekly PRO 140 injections in phase 2b trials, 10 maintained an undetectable viral load for more than two years, while four others did not report any changes in their HIV infection. The last patient moved away and could not be monitored.
Pourhassan is confident that the phase 3 trial findings will help determine which patients can achieve long-term HIV suppression and ultimately secure label expansion for PRO 140 as a single agent therapy, given it has low toxicity and virtually no side effects. PRO 140 only targets HIV patients with the R5 strain, Pourhassan added. This strain currently accounts for about 70 percent of HIV infections and 90 percent of newly-diagnosed cases in the United States.
For more information, visit www.cytodyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Sheen, who revealed his HIV status in November last year, has been a part of the study for eight months and is receiving weekly injections of the drug, the report said. The phase 3 study is looking into PRO 140’s safety and effectiveness in HIV patients and is being administered without any other HIV medication to determine whether it alone is enough to fight HIV and help subjects achieve an undetectable viral load.
Cytodyn, a biotech company that focuses on the development of innovative antibody therapies against the human immunodeficiency virus and other diseases, has not officially commented on the Daily Mail report. In a press release this week, however, it announced that several patients have already been treated with PRO 140 as part of the phase 3, multicenter clinical trial which will enroll a total of 300 subjects. All the patients included in the study have CCR5-tropic HIV-1 infection and are clinically stable, being on highly active antiretroviral therapy up to one week after the enrollment.
During the phase 3 trial, the subjects will receive only PRO 140 in the form of subcutaneous injections for 48 weeks to determine whether the product candidate is safe and efficient as a single-agent maintenance therapy for chronic suppression of HIV. PRO 140 is a fully humanized monoclonal antibody that specifically targets the CCR5 entry receptor on CD4 cells, which HIV targets and takes over. The proprietary therapy fights HIV by blocking this entry point and preventing the virus from infecting healthy cells.
CytoDyn CEO and President Nader Pourhassan, Ph.D. said his company expects the monotherapy trial to yield significant results and provide sufficient data to support further clinical and regulatory advancement of the treatment. He explained that the phase 3 trial is nearly a duplicate of the phase 2b trial that ended last year, with an additional objective of determining why some R5 patients are not responding to the therapy as well as others. Out of 15 subjects who continued the trial in the extension arm and received weekly PRO 140 injections in phase 2b trials, 10 maintained an undetectable viral load for more than two years, while four others did not report any changes in their HIV infection. The last patient moved away and could not be monitored.
Pourhassan is confident that the phase 3 trial findings will help determine which patients can achieve long-term HIV suppression and ultimately secure label expansion for PRO 140 as a single agent therapy, given it has low toxicity and virtually no side effects. PRO 140 only targets HIV patients with the R5 strain, Pourhassan added. This strain currently accounts for about 70 percent of HIV infections and 90 percent of newly-diagnosed cases in the United States.
For more information, visit www.cytodyn.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, December 14, 2016
Singlepoint, Inc. (SING) Maintaining a Positive Outlook on the Future of Marijuana Sales Processing
Despite California still looking to Trump to address marijuana industry banking challenges, Singlepoint, Inc. (OTC: SING) is maintaining a positive outlook on the future of marijuana sales processing in the state. An article by Above the Law (http://dtn.fm/p18Am) suggests that California may be able to secure bank accounts relating to cannabis businesses as long as the FinCEN cannabis banking guidelines from 2014 hold up and certain enterprising financial institutions become more willing to experiment.
As a result of the passing of Proposition 64, many are confident that some of California’s financial institutions will be taking advantage of FinCEN’s 2014 guidelines by opening accounts for cannabis-related businesses. Despite there being worries of potential U.S. Attorney General, Jeff Sessions, or newly-elected President, Donald Trump, ordering the nullification of the Cole Memo, Trump has often stated that he believes these matters should be left to individual states to decide upon, a point brought forward during a recent interview with Singlepoint CEO Greg Lambrecht (http://dtn.fm/6rejK).
Singlepoint is a holding company for a number of companies, including SingleSeed, an organization focused on providing efficient payment processing services to cannabis dispensaries in the U.S. The company started offering these services several years ago and intends to leverage its position as a ‘first mover’ in the marketplace after this year’s multi-state legalization of recreational marijuana.
During his interview on MoneyTV, Lambrecht shared the fact that the company has recently acquired the attention of a number of dispensaries interested in its services. According to the CEO, the company is redesigning the SingleSeed website in anticipation of the verdict on whether or not it will be able to aid cannabis businesses with their payment solutions moving forward. The company’s website revamp is expected to allow dispensaries to sign up in order for them to use a legal text message marketing program which will enable them to better communicate with their audiences.
This move will allow SingleSeed to start planning for the future, giving clients a head start and making the company a serious ‘first mover’ compared to competitors in the space. Although nothing is set in stone as to whether or not new laws will be put in place regarding the payment processing around the cannabis industry, Lambrecht stated that he believes decisions will be made as early as the first quarter of the coming year.
For more information, visit the company’s website at www.Singlepoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
As a result of the passing of Proposition 64, many are confident that some of California’s financial institutions will be taking advantage of FinCEN’s 2014 guidelines by opening accounts for cannabis-related businesses. Despite there being worries of potential U.S. Attorney General, Jeff Sessions, or newly-elected President, Donald Trump, ordering the nullification of the Cole Memo, Trump has often stated that he believes these matters should be left to individual states to decide upon, a point brought forward during a recent interview with Singlepoint CEO Greg Lambrecht (http://dtn.fm/6rejK).
Singlepoint is a holding company for a number of companies, including SingleSeed, an organization focused on providing efficient payment processing services to cannabis dispensaries in the U.S. The company started offering these services several years ago and intends to leverage its position as a ‘first mover’ in the marketplace after this year’s multi-state legalization of recreational marijuana.
During his interview on MoneyTV, Lambrecht shared the fact that the company has recently acquired the attention of a number of dispensaries interested in its services. According to the CEO, the company is redesigning the SingleSeed website in anticipation of the verdict on whether or not it will be able to aid cannabis businesses with their payment solutions moving forward. The company’s website revamp is expected to allow dispensaries to sign up in order for them to use a legal text message marketing program which will enable them to better communicate with their audiences.
This move will allow SingleSeed to start planning for the future, giving clients a head start and making the company a serious ‘first mover’ compared to competitors in the space. Although nothing is set in stone as to whether or not new laws will be put in place regarding the payment processing around the cannabis industry, Lambrecht stated that he believes decisions will be made as early as the first quarter of the coming year.
For more information, visit the company’s website at www.Singlepoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monaker Group, Inc. (MKGI) Making Travel Planning Easier Through Its Flagship NextTrip.com
According to 4Hoteliers (http://dtn.fm/zOeA9), 85% of travelers across the world are also smartphone users. The article goes on to state that 32% of these travelers use their mobile devices to book travel-related services. The company’s recent webinar, ‘Digital Marketing and Mobile Trends Impacting the Travel Industry’, showed that over 70% of travelers use mobile devices to check their itineraries.
But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital marketing trends transforming the travel industry, according to Smart Insights (http://dtn.fm/DoC4q). Because travel arrangements are now largely made via the Internet, and the typical consumer is looking for more than just a basic holiday, organizations in the travel industry are having to adapt to a more digital and mobile way of reaching consumers.
During a survey undertaken by Opera Mediaworks (http://dtn.fm/J9gWx), one in three people said that the availability of booking apps would make them more likely to book via mobile, and one in three also said that having research apps available could make them more likely to engage in more travel activities such as eating out, visiting various sights, and more. According to the ‘How People Use Their Phones For Travel’ research published by Google (http://dtn.fm/B5iX2), the top motivating factor for downloading travel apps is to make a specific activity or task easier. Users shared that what they find most valuable about travel apps is the wide range of features and the fact that apps store preferences that make future activities easier.
As a result, NextTrip.com, flagship company of Monaker Group, Inc. (OTCQB: MKGI), designed its own all-in-one travel planner, which gives travelers access to a range of free tools that allow them to import all booking details into one space. The free travel organizer allows users to discover hotels, restaurants, sights, and activities near their points of interest. The all-in-one travel planner helps holidaymakers organize details of their trips, and even split and collect money between groups of people. NextTrip’s travel planner is easy to use, easily accessible, and makes planning a trip while on the move simple thanks to its compatibility with mobile devices.
For more information, visit www.MonakerGroup.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital marketing trends transforming the travel industry, according to Smart Insights (http://dtn.fm/DoC4q). Because travel arrangements are now largely made via the Internet, and the typical consumer is looking for more than just a basic holiday, organizations in the travel industry are having to adapt to a more digital and mobile way of reaching consumers.
During a survey undertaken by Opera Mediaworks (http://dtn.fm/J9gWx), one in three people said that the availability of booking apps would make them more likely to book via mobile, and one in three also said that having research apps available could make them more likely to engage in more travel activities such as eating out, visiting various sights, and more. According to the ‘How People Use Their Phones For Travel’ research published by Google (http://dtn.fm/B5iX2), the top motivating factor for downloading travel apps is to make a specific activity or task easier. Users shared that what they find most valuable about travel apps is the wide range of features and the fact that apps store preferences that make future activities easier.
As a result, NextTrip.com, flagship company of Monaker Group, Inc. (OTCQB: MKGI), designed its own all-in-one travel planner, which gives travelers access to a range of free tools that allow them to import all booking details into one space. The free travel organizer allows users to discover hotels, restaurants, sights, and activities near their points of interest. The all-in-one travel planner helps holidaymakers organize details of their trips, and even split and collect money between groups of people. NextTrip’s travel planner is easy to use, easily accessible, and makes planning a trip while on the move simple thanks to its compatibility with mobile devices.
For more information, visit www.MonakerGroup.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
eXp World Holdings, Inc. (EXPI) Maintaining a Positive Outlook for the Real Estate Industry in the U.S.
eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for the agent-owned cloud-brokerage eXp Realty LLC, is maintaining a positive attitude toward the coming year. Most recently, RISMedia (http://dtn.fm/6JKt6) published a study highlighting the fact that more real estate executives are confident about their own local economies than about the world economy. Yet many real estate executives are concerned about risks posed by rising costs for traditional real estate, especially if the market should slump.
eXp World Holdings, Inc. is of the same opinion, pointing out that expenditures on brick and mortar facilities would remain fixed in the face of falling profits. According to EXPI: “Physical brick and mortar offices are of diminishing utility but represent a steady and escalating expense that erodes profits.”
EXPI has therefore used the emergence of the Internet as a force to drive advertising, leads, and sales, without the need for brick and mortar offices. By becoming a cloud-based brokerage and adopting a number of cloud-based technologies, EXPI has been able to not only cut out redundant staffing costs but also cut down on ancillary costs such as utility bills, rent, CAM, and furnishings, which are associated with brick and mortar locations.
As a result of the organization’s ability, from the beginning, to evolve with technological advancement and reduce costs by adopting a cloud-based environment, EXPI was voted second on this year’s Top Workplaces list among small-employer winners, according to NewsOK (http://dtn.fm/U0od2). In addition, Fundamental Research Corp. (http://dtn.fm/0a6S1), a research firm that initiated coverage of eXp World Holdings in April 2016, updated its analysis of the company, giving EXPI a price target of $6.78 per share compared to its previous objective of $4.06. The upward revision is based on EXPI’s record third quarter revenues, the change in its long term projections, and its healthy balance sheet.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
eXp World Holdings, Inc. is of the same opinion, pointing out that expenditures on brick and mortar facilities would remain fixed in the face of falling profits. According to EXPI: “Physical brick and mortar offices are of diminishing utility but represent a steady and escalating expense that erodes profits.”
EXPI has therefore used the emergence of the Internet as a force to drive advertising, leads, and sales, without the need for brick and mortar offices. By becoming a cloud-based brokerage and adopting a number of cloud-based technologies, EXPI has been able to not only cut out redundant staffing costs but also cut down on ancillary costs such as utility bills, rent, CAM, and furnishings, which are associated with brick and mortar locations.
As a result of the organization’s ability, from the beginning, to evolve with technological advancement and reduce costs by adopting a cloud-based environment, EXPI was voted second on this year’s Top Workplaces list among small-employer winners, according to NewsOK (http://dtn.fm/U0od2). In addition, Fundamental Research Corp. (http://dtn.fm/0a6S1), a research firm that initiated coverage of eXp World Holdings in April 2016, updated its analysis of the company, giving EXPI a price target of $6.78 per share compared to its previous objective of $4.06. The upward revision is based on EXPI’s record third quarter revenues, the change in its long term projections, and its healthy balance sheet.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, December 13, 2016
eXp World Holdings, Inc. (EXPI) Announces eXp Realty’s Reception of the Oklahoma 2016 Top Workplaces Award
In a news release issued late Monday, eXp World Holdings, Inc. (OTCQB: EXPI) announced that eXp Realty, the company’s full-service real estate brokerage, was recently recognized as one of the top workplaces in the state of Oklahoma by The Oklahoman newspaper. Based upon feedback from workplace members gathered through independent surveys by both The Oklahoman and Workplace Dynamics, the Agent-Owned Cloud Brokerage® earned the second spot in the annual list’s small-employer category, joining an impressive roster of 17 ‘Top Workplaces’ newcomers.
“This is a tremendous honor for all of the agents and brokers who are on our team,” Micah Mruwat, the company’s broker and leader in Oklahoma City, stated in yesterday’s news release. “This award speaks to the collaborative, engaging and rewarding environment of our company, not just here but in and across all eXp markets.”
Indeed, eXp Realty’s recent success has spanned markets across the country. In June of this year, the company earned a spot on similar lists recognizing the top workplaces in Washington, D.C. and Atlanta. Notably, eXp Realty’s inclusion on The Atlanta Journal-Constitution list marked the second consecutive year that the company has been recognized as a top workplace in Georgia’s capital city. When speaking to eXp Realty’s recent success in achieving these honors, Jason Gesing, the brokerage’s chief executive officer, highlighted the quality of the company’s growing collection of agent-owners.
“The synergy among our agents and brokers in Oklahoma is reflective of strong leadership in the state but also demonstrates agent-ownership’s impact on organizational health, culture, and shared sense of purpose,” he stated in yesterday’s news release. “At eXp Realty, our agents are both our shareholders and our customers. Their voices ring loudest and their opinions matter most which is what makes this award, and each Top Workplace recognition, so meaningful.”
By creating a rewarding work environment for some of the top real estate professionals in the country, eXp Realty has also been able to record tremendous growth since the beginning of 2016. On January 1, the company reported a base of 864 agents across its markets in the United States and Canada. By November, this figure had expanded to more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. Upon the release of its third quarter fiscal results last month, EXPI gave prospective shareholders some insight into the financial ramifications of this strong market performance.
During the three-month period ended September 30, 2016, EXPI recorded total revenues of $15.7 million, a year-over-year increase of 112 percent. Likewise, the company’s cash and cash equivalents at the end of the quarter were up 110 percent from the comparable period of 2015. These results, when combined with EXPI’s healthy balance sheet, quickly caught the attention of industry analysts. Less than a week after the company released its Q3 results, independent research firm Fundamental Research Corp. updated its coverage of the company and raised its fair value estimate on EXPI from $4.06 to $6.78 per share (http://dtn.fm/WOyf0).
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“This is a tremendous honor for all of the agents and brokers who are on our team,” Micah Mruwat, the company’s broker and leader in Oklahoma City, stated in yesterday’s news release. “This award speaks to the collaborative, engaging and rewarding environment of our company, not just here but in and across all eXp markets.”
Indeed, eXp Realty’s recent success has spanned markets across the country. In June of this year, the company earned a spot on similar lists recognizing the top workplaces in Washington, D.C. and Atlanta. Notably, eXp Realty’s inclusion on The Atlanta Journal-Constitution list marked the second consecutive year that the company has been recognized as a top workplace in Georgia’s capital city. When speaking to eXp Realty’s recent success in achieving these honors, Jason Gesing, the brokerage’s chief executive officer, highlighted the quality of the company’s growing collection of agent-owners.
“The synergy among our agents and brokers in Oklahoma is reflective of strong leadership in the state but also demonstrates agent-ownership’s impact on organizational health, culture, and shared sense of purpose,” he stated in yesterday’s news release. “At eXp Realty, our agents are both our shareholders and our customers. Their voices ring loudest and their opinions matter most which is what makes this award, and each Top Workplace recognition, so meaningful.”
By creating a rewarding work environment for some of the top real estate professionals in the country, eXp Realty has also been able to record tremendous growth since the beginning of 2016. On January 1, the company reported a base of 864 agents across its markets in the United States and Canada. By November, this figure had expanded to more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. Upon the release of its third quarter fiscal results last month, EXPI gave prospective shareholders some insight into the financial ramifications of this strong market performance.
During the three-month period ended September 30, 2016, EXPI recorded total revenues of $15.7 million, a year-over-year increase of 112 percent. Likewise, the company’s cash and cash equivalents at the end of the quarter were up 110 percent from the comparable period of 2015. These results, when combined with EXPI’s healthy balance sheet, quickly caught the attention of industry analysts. Less than a week after the company released its Q3 results, independent research firm Fundamental Research Corp. updated its coverage of the company and raised its fair value estimate on EXPI from $4.06 to $6.78 per share (http://dtn.fm/WOyf0).
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Friday, December 9, 2016
MediWound Ltd. (MDWD) Receives Consensus Analysts Rating of ‘Buy’
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company in the business of developing, manufacturing, and globally commercializing products that treat severe burns and wounds. In 2012, MediWound’s innovative drug, NexoBrid™, a burn and wound eschar removal agent, was approved by the European Medicines Agency (EMA) via a centralized procedure. The drug was given orphan indication for removal of dead and damaged skin in adults with burns that are deep partial and full thickness thermal burns.
NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on NexoBrid™ in the U.S. and pediatric study. The company also has two other products in its pipeline: EscharEx, which is in its phase II study and is for use in patients with chronic wounds, and MWPC003, which is about to enter its phase I study and is for use in patients with connective tissues disorders.
In November of this year, MediWound Ltd. announced third quarter 2016 financial results for the three- and nine-month periods ended September 30, 2016. The company reported revenue for the quarter of $518,000, compared to just over $100,000 for the same quarter of 2015. This was put down to the growing sales of NexoBrid™. The nine-month period results showed total revenue of $1.1 million, compared to $0.3 million for the same nine-month period of the previous year. MDWD will be spending the remainder of 2016 investing primarily in sales and marketing activities relating to the further adoption of NexoBrid™ in Europe.
Aegis Capital Corp. (http://dtn.fm/l63Bn) initiated coverage on MediWound Ltd., giving the company a ‘Buy’ rating with a price target of $11 per share. This rating was given based on the fact that the company has made significant progress in the area of wound debridement. According to the report, MDWD’s NexoBrid™ is showing significantly faster, more selective, safer, and more cost efficient results compared to current treatments. The report also highlights the possibility for the company to integrate into the chronic wound care market with EscharEx and markets relating to connective tissue disorders with its pipeline product MWPC003.
Despite Zacks Investment Research lowering the company’s status from a ‘Buy’ rating to a ‘Hold’ rating, six other research analysts have given MDWD a ‘Buy’ rating, and Wells Fargo & Co. offered MediWound an ‘Outperform’ rating with a price target on the stock of $14. The company has a consensus ‘Buy’ rating with a consensus price target of $13.25, all according to Cerbat Gem Market News and Analysis (http://dtn.fm/Ch85p).
Institutional investors and hedge funds are now said to own over 27% of MediWound shares, after Migdal Insurance & Finance Holdings, Wells Fargo & Company MN, and Oppenheimer & Co. bought new positions in the company’s stock. Wellington Management Group LLP and United Services Automobile Association also increased their positions in MediWound. As of this writing, the company has a market cap of $107.17 million, with an enterprise value at $84.15 million, and shares currently selling at around $4.90 per share.
For more information, visit the company’s website at www.mediwound.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on NexoBrid™ in the U.S. and pediatric study. The company also has two other products in its pipeline: EscharEx, which is in its phase II study and is for use in patients with chronic wounds, and MWPC003, which is about to enter its phase I study and is for use in patients with connective tissues disorders.
In November of this year, MediWound Ltd. announced third quarter 2016 financial results for the three- and nine-month periods ended September 30, 2016. The company reported revenue for the quarter of $518,000, compared to just over $100,000 for the same quarter of 2015. This was put down to the growing sales of NexoBrid™. The nine-month period results showed total revenue of $1.1 million, compared to $0.3 million for the same nine-month period of the previous year. MDWD will be spending the remainder of 2016 investing primarily in sales and marketing activities relating to the further adoption of NexoBrid™ in Europe.
Aegis Capital Corp. (http://dtn.fm/l63Bn) initiated coverage on MediWound Ltd., giving the company a ‘Buy’ rating with a price target of $11 per share. This rating was given based on the fact that the company has made significant progress in the area of wound debridement. According to the report, MDWD’s NexoBrid™ is showing significantly faster, more selective, safer, and more cost efficient results compared to current treatments. The report also highlights the possibility for the company to integrate into the chronic wound care market with EscharEx and markets relating to connective tissue disorders with its pipeline product MWPC003.
Despite Zacks Investment Research lowering the company’s status from a ‘Buy’ rating to a ‘Hold’ rating, six other research analysts have given MDWD a ‘Buy’ rating, and Wells Fargo & Co. offered MediWound an ‘Outperform’ rating with a price target on the stock of $14. The company has a consensus ‘Buy’ rating with a consensus price target of $13.25, all according to Cerbat Gem Market News and Analysis (http://dtn.fm/Ch85p).
Institutional investors and hedge funds are now said to own over 27% of MediWound shares, after Migdal Insurance & Finance Holdings, Wells Fargo & Company MN, and Oppenheimer & Co. bought new positions in the company’s stock. Wellington Management Group LLP and United Services Automobile Association also increased their positions in MediWound. As of this writing, the company has a market cap of $107.17 million, with an enterprise value at $84.15 million, and shares currently selling at around $4.90 per share.
For more information, visit the company’s website at www.mediwound.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Globus Medical, Inc. (GMED) Class A Stock Sees Significant Volume Spike Moving Into 2017
As an eventful year for Globus Medical, Inc. (NYSE: GMED) is nearing an end, the leading medical device company experienced a substantial surge in trading volume on December 06. Equities.com (http://dtn.fm/Rab1C) noted a 1.3% gain of Globus Medical, Inc. Class A stock, closing at $23.31. The stock, which averages a daily volume of 1.11 million shares over the last month, captured the attention of numerous institutional investors and analysts when a surge of 11.57 million shares traded hands on 28,116 trades. The article states, “Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price.”
Increased awareness has been building for the medical device company during 2016, including the unveiling of its investigational robotics system Excelsius at the 2016 North American Spine Society (NASS) meeting held in late October. Per articles from MassDevice.com (http://dtn.fm/Of7Fc), and Becker’s Spine Review (http://dtn.fm/9t2Mm), Globus Medical expressed its anticipation of an approval and launch of the platform in early to mid-2017 to investment bank Leerink Partners. The MassDevice.com article also states that Leerink spoke with surgeons who were very interested in a trial of the platform as it becomes available. This adds credence to the company’s position as one of the “three main players” in the burgeoning surgical robotics industry (http://dtn.fm/u9oeH), citing recent commentary from the Medical Device and Diagnostic Industry website. MDDI mentions that surgical robots are only used in roughly 5% of spine procedures today, but that a survey by RBC Capital Markets indicates the potential for rapid adoption growth.
This potential for mass adoption has also been noted by financial analysis firm, Aegis Capital (http://dtn.fm/s1Rhi), in a report from November 30th that preceded Tuesday’s surge in trading activity. The firm set a $31 target price that was achieved, in part, by Globus Medical’s promising pipeline of emerging technologies, namely the robotics platform and trauma. The report calls attention to the system’s ability to serve as a competitor to Medtronic’s O-Arm with Stealth Station navigation. Those systems, which do not include robotic assistance, retail for more than $1 million, placing Globus Medical in a position to charge a premium on its own systems, as they incorporate full feature navigation. As a result, the company believes the customers of the roughly 900 O-Arms installed worldwide to be prospective customers and early adopters. Globus Medical intends to demonstrate, through clinical studies, the system’s time and money-saving benefits, as well as the added layer of predictability and accuracy it affords.
Headquartered in Audubon, Pennsylvania, Globus Medical, Inc. is a leading musculoskeletal implant manufacturer with the singular focus of advancing spinal surgery through the development of innovative engineering and technology. To date, Globus Medical has developed and released more than 150 spine products.
For additional information, visit www.GlobusMedical.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Increased awareness has been building for the medical device company during 2016, including the unveiling of its investigational robotics system Excelsius at the 2016 North American Spine Society (NASS) meeting held in late October. Per articles from MassDevice.com (http://dtn.fm/Of7Fc), and Becker’s Spine Review (http://dtn.fm/9t2Mm), Globus Medical expressed its anticipation of an approval and launch of the platform in early to mid-2017 to investment bank Leerink Partners. The MassDevice.com article also states that Leerink spoke with surgeons who were very interested in a trial of the platform as it becomes available. This adds credence to the company’s position as one of the “three main players” in the burgeoning surgical robotics industry (http://dtn.fm/u9oeH), citing recent commentary from the Medical Device and Diagnostic Industry website. MDDI mentions that surgical robots are only used in roughly 5% of spine procedures today, but that a survey by RBC Capital Markets indicates the potential for rapid adoption growth.
This potential for mass adoption has also been noted by financial analysis firm, Aegis Capital (http://dtn.fm/s1Rhi), in a report from November 30th that preceded Tuesday’s surge in trading activity. The firm set a $31 target price that was achieved, in part, by Globus Medical’s promising pipeline of emerging technologies, namely the robotics platform and trauma. The report calls attention to the system’s ability to serve as a competitor to Medtronic’s O-Arm with Stealth Station navigation. Those systems, which do not include robotic assistance, retail for more than $1 million, placing Globus Medical in a position to charge a premium on its own systems, as they incorporate full feature navigation. As a result, the company believes the customers of the roughly 900 O-Arms installed worldwide to be prospective customers and early adopters. Globus Medical intends to demonstrate, through clinical studies, the system’s time and money-saving benefits, as well as the added layer of predictability and accuracy it affords.
Headquartered in Audubon, Pennsylvania, Globus Medical, Inc. is a leading musculoskeletal implant manufacturer with the singular focus of advancing spinal surgery through the development of innovative engineering and technology. To date, Globus Medical has developed and released more than 150 spine products.
For additional information, visit www.GlobusMedical.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
